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ABSTRACT
ASSESSMENT OF MITOCHONDRIAL DYSFUNCTION IN LUNGS FROM RATS
EXPOSED TO HYPEROXIA AND THE EFFICACY OF DUROQUINONE
Swetha Ganesh, B.S.
Marquette University,2021
Dissipation of mitochondrial membrane potential (Δym) is a hallmark of mitochondrial
dysfunction. The objective of this thesis was to use a previously developed experimentalcomputational approach to estimate tissue Δym in intact lungs of rats exposed to
hyperoxia, and to evaluate the ability of duroquinone (DQ) to reverse any hyperoxiainduced depolarization of lung Dym. Rats were exposed to hyperoxia (>95% O2) or
normoxia (room air) for 48 hrs, after which lungs were excised and connected to a
ventilation-perfusion system. The experimental protocol consisted of measuring the
concentration of the fluorescent dye rhodamine 6G (R6G) during three single-pass
phases: loading, washing, and uncoupling, in which the lungs were perfused with and
without R6G, and with the mitochondrial uncoupler FCCP, respectively. For normoxic
lungs, the protocol was repeated with 1) rotenone (complex I inhibitor), 2) rotenone and
either DQ or its vehicle (DMSO), and 3) rotenone, glutathione (GSH), and either DQ or
DMSO added to the perfusate. Hyperoxic lungs were studied with and without DQ and
GSH added to the perfusate. Computational modeling was used to estimate lung Δym
from R6G data. The results show that rat exposure to hyperoxia caused a partial
depolarization (-38 mV) of lung Δym, and complex I inhibition depolarized lung Δym by
-90 mV. Results also demonstrate the efficacy of DQ to fully reverse both rotenoneinduced and hyperoxia-induced lung Δym depolarization. This study demonstrates
hyperoxia-induced Δym depolarization in intact lungs, and the utility of this approach for
assessing the impact of potential therapies such as exogenous quinones that target
mitochondria in intact lung.
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CHAPTER 1: INTRODUCTION, BACKGROUND, AND OBJECTIVE
1.1 Clinical Motivation

Acute lung injury (ALI) and its most severe form acute respiratory distress
syndrome (ARDS) are characterized by rapidly progressing hypoxic lung failure and
carry high morbidity and mortality rates (Laffey & Matthay, 2017). ALI/ARDS can be
initiated by direct or indirect injury to the lung (Matthay et al., 2019). Direct injury to the
lungs can be caused by pneumonia, inhalation of harmful chemicals, pulmonary tissue
injury, and indirect injury can be caused by sepsis, multiple blood transfusions and severe
trauma (Matthay et al., 2003)(Matthay et al., 2012). Direct or indirect injury to the lungs
can in turn lead to inflammation and oxidative stress which affect the bronchial
epithelium, alveolar macrophages, and vascular endothelium and disrupts the air-blood
barrier leading to a protein-rich fluid accumulation in the alveoli. This in turn impairs the
vital gas exchange function of the lungs, which in many cases can lead to multi-organ
failure and death (Han et al., 2015).
The high morbidity and mortality rates of ARDS are to a large extent due to the
lack of effective therapies (Matthay et al., 2003). Current therapies are mostly limited to
supplemental supportive care. This includes low tidal volume protective ventilation,
prone positioning, and conservative fluid management (Levitt et al., 2012). However,
mechanical ventilation can lead to lung inflammation and ventilator-induced lung injury
(Kellner et al., 2017). Studies using prophylactic aspirin, inhaled nitric oxide,
mesenchymal stem cells, and intravenous β-agonists have not shown much mortality
benefit (Ma et al., 2019). Furthering our understanding of the pathogenesis of ALI could
lead to the identification of potential therapeutic targets.
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Studies have shown that ARDS development could be in part due to dysfunction
of mitochondria bioenergetic of lungs (Cloonan et al., 2020)(Ten & Ratner, 2020). Lung
cellular mitochondria produce ~80-90% of the required ATP for the normal functioning
of cells (Fisher, 1984) (Bagkos et al., 2014). The mitochondrial membrane potential
(ΔΨm) is a major component of the proton motive force that drives the synthesis of ATP
at mitochondrial complex V and controls the rate of respiration and the generation of
reactive oxygen species (ROS) (Zorova et al., 2018). Thus, a change in the ΔΨm is an
indicator of mitochondrial dysfunction in lung cells (Audi et al., 2020).
Fluorescent lipophilic cationic dyes have been used to probe ΔΨm mainly in
cultured cells and isolated mitochondria (Perry et al., 2011)(Scaduto & Grotyohann,
1999)(Gan et al., 2011)(Wolken & Arriaga, 2014)(Adrie et al., 2001). A small number of
studies have used these dyes to probe ΔΨm in intact functioning organs (Audi et al., 2020;
Hough et al., n.d.; Sakamuru et al., 2016; Scaduto & Grotyohann, 1999). Recently, Audi
et al. developed an experimental-computational approach for estimating ΔΨm in
millivolts (mV) in isolated perfused rat lungs using the cationic rhodamine dye
rhodamine 6G (R6G) (Audi et al., 2020). The objective of my thesis is to use this
approach to assess ΔΨm in intact lungs from rats exposed to hyperoxia (> 95% O2 for 48
hours) as a model of human ALI, and to evaluate the ability of the ubiquinone analog
duroquinone to reverse any hyperoxia-induced depolarization of ΔΨm (Audi et al., 2003,
2005).
1.2

Role of mitochondria in lung cellular functions: ATP Production
The mitochondrion is a multifunctional organelle which plays an important role in

cellular ATP synthesis, redox homeostasis, apoptosis, and intracellular energy transfer
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(Zorov et al., 2014). Figure 1 shows the key processes of oxidative phosphorylation (with
glucose as substrate) which takes place in mitochondria and is responsible for 80-90% of
ATP production in lung cells. This process begins with the cellular uptake of glucose,
which is the major substrate for lung cells under physiological conditions (Fisher, 1984).
Following its uptake, glucose is phosphorylated to glucose-6-phosphate which then enters
glycolysis resulting in the conversion of a glucose molecule to two molecules of
pyruvate. Pyruvate from glycolysis goes into the mitochondrial matrix and is converted
into a two-carbon molecule bound to Coenzyme A, known as acetyl CoA. Acetyl CoA is
a molecule that is further converted to oxaloacetate, which enters the citric acid cycle
(Krebs cycle) where it undergoes oxidation and generates electron donors such as NADH
and FADH2. The electrons are then transferred to the electron transport chain (ETC) to
reduce molecular O2 to H2O at complex IV and in the process undergo multiple redox
reactions that result in the pumping of H+ from the matrix to the intermembrane space at
complexes I, III and IV, creating a proton motive force that drives the production of ATP
from ADP and inorganic phosphate at complex V. ΔΨm is an important component of this
proton motive force.
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Figure 1: ATP is generated by oxidative phosphorylation in the inner mitochondrial
membrane conducted by the four complexes of the ETC and ATP synthase (Complex
V). Inhibition sites of the mitochondrial complex I by rotenone are represented by red
blunted arrows. G6PD catalyzes NADP+ to its reduced form, NADPH, in the pentose
phosphate pathway. Abbreviations: G6PD=Glucose-6-phosphate dehydrogenase;
ATP=Adenosine triphosphate; ADP=Adenosine diphosphate; NADP+=Nicotinamide
adenine dinucleotide phosphate [oxidized form]; NADPH=Reduced NADP;
GSSG=Oxidized glutathione; GSH=Reduced glutathione ; CytC =Cytochrome C; CoQ =
Coenzyme Q ; LDH = Lactate dehydrogenase
1.3

Rat exposure to hyperoxia as a model of human ALI:
Several rodent models of human ALI/ARDS have been developed (Kallet &

Matthay, 2013)(Crapo et al., 1980)(Sepehr et al., 2013)(Audi et al., 2005). Rat exposure
to hyperoxia (>95% O2) is a well-established animal model of human ALI/ARDS
(Sepehr et al., 2013)(Bassett et al., 1992)(Crapo et al., 1980)(Audi et al., 2017). This
model reproduces the cardinal features of clinical ALI/ARDS, namely bilateral lung
infiltration, decreased lung compliance, parenchyma injury including increased vascular
permeability, low-pressure edema, and hypoxemia (Matute-Bello et al., 2008)(Crapo et
al., 1980)(Levitt & Matthay, 2012).
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Crapo et al. studied the structural and biochemical changes in lungs from rats
following exposure to 100% O2 until death (Crapo et al., 1980). They showed that in
comparison to rats exposed to room air, no significant anatomical changes were seen in
the lungs of rats exposed to 100% O2 for up to 40 hours. By 60 hours, however, there was
a 30% loss in pulmonary capillary endothelial cells and cell surface, lung infiltration of
phagocytic leukocytes and other cells, and an increase in air-blood barrier thickness by
56%. Rats that survived 60 hours of 100% O2 exposure lost 44% of their pulmonary
capillary endothelial cells and developed edema, which results in the thickening of the
air-blood barrier, pleural effusion, severe hypoxemia, and eventually death within 72
hours (Crapo et al., 1980).
1.4
Mitochondrial changes in lungs of rodents exposed to hyperoxia as a model
of human ALI:
Inflammation, oxidative stress, and mitochondrial dysfunction has been shown to
play key roles in the pathogenesis of hyperoxia-induced ALI (Liu et al., 2017) (Liu X,
2017). Previous studies have reported hyperoxia-induced mitochondrial changes in lung
tissue/cells early in the pathogenesis of hyperoxia-induced ALI (Audi et al., 2005)(Gan et
al., 2011)(Merker et al., 2006)(Merker et al., 2007)(Sepehr et al., 2013). Sepehr et al.
reported ~77% decrease in lung tissue complex I activity per mg protein from rats
exposed to hyperoxia (>95% O2 for 48 hrs) (Sepehr et al., 2013). In the same study, they
showed using surface fluorometry that rat exposure to hyperoxia decreased rotenoneinduced change in NADH signal by 63%, as an index of lung tissue complex I activity, as
compared to that of normoxic lungs. In addition to decrease in lung tissue complex I
activity, Sepehr et al. reported a 63% decrease in mitochondrial complex II activity in
lung tissue from rats exposed to >95% O2 for 48 hours as compared to that from lungs of
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normoxic rats, and a 56% decrease in lung surface FAD signal in the presence of
potassium cyanide (complex IV inhibitor) and pentachlorophenol (mitochondrial
uncoupler), as an index of lung complex II activity. Based on these results, they
concluded that the lung tissue electron transport chain (ETC) upstream from complexes I
and II is more reduced in intact hyperoxic lungs than in normoxic lungs, and that
activities of complexes I and II are lower in hyperoxic lungs as compared to normoxic
lungs (Sepehr et al., 2013).
The above-mentioned decreases in mitochondrial complex I and II activities
following exposure to hyperoxia (> 95% O2 for 48 hours) would be expected to alter the
proton motive force and partially depolarize Dym, which in turn could alter mitochondria
bioenergetics and respiration. This is consistent with results from Audi et al. in which
they quantified Dym of isolated mitochondria from normoxic and hyperoxic lungs using
the cationic dye rhodamine 123 (R123) (Audi et al., 2017). For this preparation, the
addition of ADP (state 3) in the presence of the complex I substrates, pyruvate + malate,
or complex II substrate, succinate, stimulated transient and reversible efflux of R123
from the mitochondria and is consistent with partial depolarization of Dym. One measure
of the kinetics of ADP-stimulated Dym depolarization is the full width half maximum
time (FWHM) for R123 to return to the baseline (state 2). Audi et al. showed that rat
exposure to hyperoxia (>95% O2 for 48 hours) increased FWHM by 67% and 60% in the
presence of the complex I substates (pyruvate + malate) and complex II substrate
(succinate), respectively. This suggests that Dym recovery from ADP-induced
depolarization in mitochondria from hyperoxic lungs was substantially slower than that in
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normoxic lungs, consistent with decreases in lung tissue complex I (79%) and II (64%)
activities with hyperoxia (Sepehr et al., 2013).
Das et al. showed that exposure of mice to 90% O2 for 48 hours decreased the
activities of lung tissue complexes I and II, as well as basal, state 3 and uncoupled state 3
respiratory rates in isolated mitochondria (Das, 2013). They also determined complex IV
activity using ascorbate and concluded that hyperoxia does not affect complex IV (Das,
2013).
Fisher AB showed that rat exposure to 95% O2 for 48 hours had no effect on total
lung tissue ATP content as compared to normoxic lungs (Fisher, 1978). However, rats
exposed to hyperoxia (95% O2 for 48 hours) increased the lactate to pyruvate ratio in
lungs, which was measured as an indicator of the lung rate of ATP synthesis via the
glycolytic pathway. Lung lactate production rate increased by 61%, whereas as lung rate
of pyruvate production decreased by ~8% which led to doubling of the lactate/pyruvate
ratio. Based on these results, they concluded that hyperoxia-induced increase in
glycolytic ATP production could compensate for decrease in ATP production via
oxidative phosphorylation and that the increased lactate-to pyruvate ratio was in response
to decreased mitochondrial ATP synthesis (Fisher, 1978).
Bassett et al. showed no effect on FAD-linked metabolism in mitochondria
isolated from lungs of rats exposed to hyperoxia (100% O2 for 24 hours) (Bassett et al.,
1992). However, in the presence of NAD-linked substrates, respiratory rates were
significantly reduced. They showed that baseline and ADP-stimulated mitochondrial
respiratory rates were significantly lower in the presence of NAD-linked substrates for
mitochondria from lungs of hyperoxia-exposed rats as compared to normoxia (room air)
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exposed rats (Bassett et al., 1992). These results are consistent with a hyperoxia-induced
decrease in complex I early in the pathogenesis of hyperoxia-induced ALI.
Gan et al quantified the mitochondrial and plasma membrane potential in cultured
bovine pulmonary endothelial cells (BPECs) using the rhodamine dye R123 and TMRE
in control and hyperoxia (95% O2 for 48 hours) exposed cells by measuring the dynamic
dye concentrations in the medium (Gan et al., 2011). They showed that ΔΨm in
hyperoxia-exposed cells are more sensitive to depolarization by a mitochondrial
uncoupler than ΔΨm in normoxia-exposed cells, consistent with hyperoxia-induced
mitochondrial deficiency in BPECs (Gan et al., 2011).
Beyer et al. performed western analyses on rat lung homogenates from normoxic
and hyperoxia lungs using an antibody cocktail containing antibodies to each of the five
mitochondrial complexes and showed clear bands consistent with complexes I through V
in all samples. They showed (Figure 2) that the expressions of complexes I and II were
significantly lower in lungs samples from hyperoxia rats (Beyer et al., 2021). Hyperoxia
had no significant effects on the expressions of complexes III, IV and V.
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Figure 2: Representative western blots (left) and summary of results (right) of the
expressions of complexes I, II, III, IV and V in lung samples from normoxic and
hyperoxic rats (Beyer et al., 2021). *different from normoxia (p < 0.05)
1.5 Mitochondrial membrane potential, oxidative stress, and mitochondrial
dysfunction
ΔΨm is an important component of the proton motive force that is generated via
complexes I, III, and IV of the electron transport chain. The proton gradient and the ΔΨm
together drive the production of ATP at complex V. The direction of the ΔΨm drives the
inward transport of cations and outward transport of anions. The accumulation of cations
in the mitochondria depends on ΔΨm, which also plays a key role in transporting other
ions (other than H+) to ensure healthy functioning of mitochondria and the elimination of
disabled mitochondria. Normally, ΔΨm and ATP production rates are stable. However,
sustained changes in the ΔΨm and in turn in cellular ATP production are considered
indicators of various pathologies which are depicted by either depolarized or
hyperpolarized ΔΨm. A depolarized ΔΨm is potentially very harmful to cells since it
reduces the production of ATP (Zorova et al., 2018).
ΔΨm is a result of redox transformations that occur in the TCA cycle. It is an
intermediary energy storage which is utilized by the ATP synthase (complex V) to
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produce ATP and is the most reliable indicator of mitochondrial function (Zorova et al.,
2018)(Bagkos et al., 2014). Various studies have shown that the range for ΔΨm measured
from the rat’s lungs, heart, liver and cultured neurons is between -125 to -150 mV for
maximum production of ATP (Bagkos et al., 2014)(Alpert et al., 2018)( Hassinen et al.,
1984)(Wan et al., 1993)(Audi et al., 2020). Depolarization of ΔΨm, and thus lower ATP
production rate, lead to mitochondrial dysfunction which is a key factor in the
pathogenesis of ALI/ARDS (Bagkos et al., 2014)(Schumacker et al., 2014). Loss of lung
air-blood barrier is caused in part by mitochondrial dysfunction which can lead to
endothelial/epithelial cell death (Cloonan et al., 2020)(Levitt & Matthay, 2012). This in
part can allow neutrophils to pass across the barrier and induce additional tissue damage
by producing cytotoxic secretions (Mittal et al., 2014), such as ROS, pro-inflammatory
cytokines, bioactive lipids, all important factors in the pathogenesis of ALI/ARDS
(Kellner et al., 2017).
There are many sources of reactive oxygen species (ROS) in the cells, including
NADPH oxidases (NOX), xanthine oxidase, and mitochondria (Kellner et al., 2017). In
controlled quantities, ROS are critical in signaling growth, differentiation, progression
(Zhang et al., 2016). Increased or uncontrolled ROS production by lung cells can lead to
the disruption of the lung capillary endothelial barrier and alveolar epithelium increasing
the vascular leakage resulting in pulmonary edema (Kellner et al., 2017).
The electrons in complex I donated from NADH are transported through the FMN
(flavoprotein), Fe-S clusters and then to the ubiquinone Q. The ROS superoxide (O2-) is
produced at each of these steps by complex I. Complex III produces O2- during the Q
cycle, which is the transfer of electrons from complexes I and II to complex III and in
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turn reduces ubiquinone to ubiquinol. Oxidation of ubiquinol donates two electrons to
cytochrome c and results in an unstable ubisemiquinone and donates a single electron to
O2, generating O2- which gets converted to H2O2 within the mitochondria and diffuses to
the cytoplasmic compartment. Hyperoxia-induced increase in ROS formation could
damage the complex I activity by oxidizing the lipid cardiolipin, which is sensitive to
ROS (Sepehr et al., 2013). Since complex II is encoded by nuclear DNA, damage to
mDNA due to hyperoxia-induced increase in the rate of ROS formation should not affect
complex II. However the apparent decrease in complex II activity could be a
compensatory mechanism by the cells to reduce ROS formation under hyperoxic
conditions (Sepehr et al., 2013). Damage to complex I and complex III can lead to
significant decrease in mitochondrial ATP production.
An increase in ROS can produce extremely harmful effects and if not balanced by
antioxidants, can lead to chronic inflammatory conditions (Pizzino et al., 2017). The
imbalance in the oxidants and antioxidants produces oxidative stress. Glutathione (GSH)
is an antioxidant which, in its reduced form, usually modulates the levels of ROS
produced by donating a proton to neutralize H2O2 (Presnell et al., 2013). The ability to
neutralize ROS depends on the GSH/GSSG concentration which decreases with oxidative
stress (Aquilano et al., 2014). The mitochondria are one of the key sources of ROS
generation which greatly depend on the ΔΨm. Depolarization of ΔΨm can exponentially
increase mitochondrial ROS production (Gao et al., 2008).
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Figure 3: The effect of ROS on the mitochondria affecting the ability of Mitochondria to
produce ATP. Oxidative stress in the mitochondria releases cytochrome C into the
cytosol and leads to apoptosis. It can also lead to membrane damage and increase the
permeability making the inner membrane more permeable to small molecules.
Mitochondrial ROS is also an important cell signaling pathway and modulates various
cell functions (Galley, 2011).
1.6 Methods to measure ΔΨm:
Various cationic fluorescence dyes have been used to assess ΔΨm mostly in reduced
systems, including isolated mitochondria or cultured cells (Perry et al., 2011)(Scaduto &
Grotyohann, 1999)(Gan et al., 2011)(Adrie et al., 2001). Limited studies have attempted
to measure ΔΨm in intact functioning lungs (Sakamuru et al., 2016)(Hough et al., 2019)
(Audi et al., 2020).
Arriaga et al. used the method of capillary electrophoresis with laser-induced
fluorescence detection to measure ΔΨm in isolated mitochondria from mouse liver and
muscle cells (Arriaga et al., 2014). JC-1 was used as the fluorescence probe in isolated
mitochondria and red/green fluorescence intensity ratios from individual mitochondria
were used as an indicator of mitochondrial membrane potential (Arriaga et al., 2014).
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However, the disadvantage of using JC-1 is that it is sensitive to factors other than the
ΔΨm, such as surface/volume ratio due to aggregation (Perry et al., 2011).
Baraccaa et al. assessed mitochondrial respiration and membrane potential
(bioenergetics) in isolated rat liver mitochondria using the dye rhodamine 123 (R123
(Baracca et al., 2003). Mitochondrial respiration was measured under four respiratory
states. State 1 is the condition under which isolated mitochondria are added to the
respiration buffer with no substrates. State 2 is the respiratory state following the addition
of complex I substrates such as pyruvate and malate or complex II substates such as
succinate to the respiration buffer. State 3 respiration is reached following the addition of
high concentrations of ADP which is converted to ATP (Lanza & Nair, 2009). State 3 is
characterized as the state with saturating ATP usage/production (Korzeniewski, 2015).
State 4 is the respiratory state that is reached following the full conversion of added ADP
to ATP (Lanza & Nair, 2009) (Korzeniewski, 2015). The uncoupled respiration is
achieved by adding an uncoupler (FCCP) which causes dissipation of the proton gradient
across the inner mitochondrial membrane. They showed that the dynamic and steadystate R123 redistribution across the inner mitochondrial membrane can be used to detect
membrane potential changes by measuring the rate of fluorescence quenching (Baracca et
al., 2003).
Johnson et al. used cationic fluorescence probes such as rhodamines B, 3B, 6G,
19, 110, 116, 123, and tetramethyl rhodamine, ANS, merocyanine 540 and fluorescein in
a variety of living cells to monitor ΔΨm using fluorescence microscopy (Johnson et al.,
1981). The results show that differences in the intensity of mitochondrial-associated
fluorescence can reflect the functional state of mitochondria. The variations in
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mitochondrial membrane potential and the accumulation of the cationic compounds may
be an indicator for increased ATP requirements (Johnson et al., 1981).
Gan et al. developed an experimental and computational approach for evaluating
ΔΨm and plasma membrane potential in cultured bovine pulmonary arterial endothelial
cells. The study involved the addition of a rhodamine dye to the medium containing the
cells and measuring the dye medium concentrations over time (Gan et al., 2011). They
used computational modeling to estimate the values of ΔΨm and plasma membrane
potential (in mV) from the dynamic medium dye concentrations. Their results show that
for cells exposed to hyperoxia (95% O2 for 48 hours), their ΔΨm is more sensitive to
depolarization than control cells (exposed to room air) (Gan et al., 2011).
Scaduto et al. measured ΔΨm in isolated perfused rat heart and isolated
mitochondria from rat heart using the rhodamine cationic dye TMRM (Scaduto &
Grotyohann, 1999). The ΔΨm in isolated perfused heart was measured from the surface
emission fluorescence of the dye. The fluorescence properties were found to change upon
accumulation in the mitochondria causing a red shift in the wavelength which was used to
measure ΔΨm by fluorescence ratio method. However, they were not able to observe the
spectral shift in the TMRM loaded rat heart due to accumulation of the dye in both
mitochondria and the cytosol (Scaduto & Grotyohann, 1999) .
Hough et al. assessed the ΔΨm in isolated intact mice lungs by inducing chemical
injury with HCl using an alveolar micro puncture technique (Hough et al., 2019). They
used confocal microscopy to measure the change in the fluorescence intensity from
TMRE in microvascular endothelial cells as an index of ΔΨm, before and after inducing
injury with HCl. The acid injection decreased the TMRE fluorescence indicating the
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mitochondrial depolarization in the endothelial cells. This approach is limited to
measuring the change in ΔΨm in a localized lung region and therefore does not measure
the overall change in ΔΨm in the lungs (Hough et al., 2019).
Audi et al. developed an experimental and computational approach for measuring
the ΔΨm in intact functioning rat lungs (Audi et al., 2020). The approach involves
measuring the concentration of cationic fluorescent dye rhodamine 6G (R6G) in the lung
venous effluent following its infusion through the pulmonary artery. A physiologicalbased pharmacokinetic (PBPK) model of the pulmonary disposition of R6G was then
used for quantitative interpretation of the data and for estimating the value of the lung
ΔΨm (in mV). The objective of this thesis is to make use of this approach to assess the
effect of rat exposure to hyperoxia (>95% O2 for 48 hours) as a model of clinical acute
lung injury.
1.7
Potential utility of exogenous quinone compounds to reverse mitochondrial
dysfunction due to decreases in complex I and/or II activities.
Previous studies assessed the disposition of the quinone compounds duroquinone
(DQ) and coenzyme Q1 (CoQ1) in isolated perfused rat lungs and cultured pulmonary
endothelial cells (Audi et al., 2003)(Audi et al., 2005)(Merker et al., 2004). They showed
that the two-electron reduction of DQ to durohydroquinone (DQH2) was predominantly
via the cytosolic enzyme NAD(P)H quinone dehydrogenase 1 (NQO1), and that the
oxidation of DQH2 back to DQ is via mitochondrial complex III (Figure 3). For CoQ1,
they showed that its two-electron reduction to coenzyme Q1 hydroquinone (CoQ1H2) is
via NQO1 and mitochondrial complex I, and that the oxidation of CoQ1H2 is via
mitochondrial complex III (Figure 3).
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Previous studies in cultured bovine pulmonary endothelial cells reported
hyperoxia-induced changes in the reduction rate of DQ to DQH2 and CoQ1 to CoQ1H2
(Merker et al., 2007)(Merker et al., 2006)(Audi et al., 2005). The results showed that the
reduction rate of CoQ1 to CoQ1H2, oxygen consumption rates and complex I activity
were reduced in hyperoxia–exposed cells as compared to those for normoxia cells. On the
other hand, they showed that hyperoxia exposure resulted in an increase in the reduction
of DQ to DQH2 via an increase in NQO1 protein and activity when compared to the
normoxia endothelial cells.

Figure 4: Enzyme mediated reduction of quinones and their inhibitors (Gan, 2011).
NQO1: NAD(P)H quinone dehydrogenase 1 is a cytosolic enzyme.
Audi et al. assessed the disposition of DQ in isolated perfused rat lungs (Audi et
al., 2003). They showed that inhibition of complex I and II reduced lung O2 consumption
by ~60%, and that this decrease was reversible with the addition of DQ to the
recirculating lung perfusate.
Bongard et al. evaluated the effect of the complex I inhibitor rotenone on
mitochondrial bioenergetics and respiration in cultured rat microvasculature pulmonary
endothelial cells and in intact rats lungs, and assessed the efficacy of CoQ1 in reversing
rotenone-induced mitochondrial dysfunction (Bongard et al., 2013) (Bongard et al.,
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2015). They showed that inhibition of complex I with rotenone decreased lung ATP,
increased lactate/pyruvate ratio, as an index of glycolic pathway, and increased
pulmonary vascular endothelial filtration coefficient (Kf). Results in cell studies showed
that complex I inhibitors affected the O2 consumption, cell monolayer permeability and
ΔΨm depolarization. Furthermore, they showed that CoQ1 was able to fully reverse these
rotenone-induced mitochondrial and permeability changes in intact lungs and cultured
cells (Bongard et al., 2015).
Chan et al. assessed the ability of CoQ1 to reverse rotenone-induced
mitochondrial dysfunction in cultured hepatocytes (Chan et al., 2002). They showed that
inhibition of complex I using rotenone led to cytotoxicity, including collapse of ΔΨm,
decrease in mitochondrial ATP production, and increase in ROS formation. The addition
of CoQ1 to the cell medium reversed the cytotoxic effects of rotenone (Chan et al., 2002).
As expected, inhibiting complex III with antimycin prevented CoQ1 from reversing
rotenone-induced ΔΨm depolarization, cytotoxicity, and cellular ATP depletion (Chan et
al., 2002).
The above results suggest that the addition of DQ or CoQ1 to lung perfusate could
be used to overcome the effects of hyperoxia-induced decreases in lung mitochondrial
complex I and II activities on mitochondrial ETC bioenergetics/respiration.
OBJECTIVE and SPECIFIC AIMS:
The objectives of this thesis are to 1) assess mitochondrial dysfunction in isolated
perfused lungs from rats exposed to hyperoxia as a model of human ALI, and 2) evaluate
the efficacy of DQ for reversing hyperoxia-induced mitochondrial dysfunction. The overall
hypothesis is that rat exposure to hyperoxia depolarizes the lung mitochondrial membrane
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potential mainly due to a decrease in mitochondrial complexes I and II activities, and that
this depolarization can be detected in isolated perfused lungs using R6G. Furthermore, we
hypothesize that this depolarization can be reversed using DQ. We tested these hypotheses
using the following specific aims.
Aim # 1: Assess ΔΨm in lungs from rats exposed to hyperoxia as a model of human
ALI. Rats will be exposed to > 95% O2 (hyperoxia) or room air (normoxia) for 48 hours
after which the lungs will be isolated and connected to a ventilation-perfusion system for
measuring the disposition of R6G using the experimental-computational approach
developed by Audi et. al (Audi et al., 2020). ΔΨm (in mV) will be estimated from the
resulting dynamic R6G venous effluent concentrations using a previously developed
physiologically based pharmacokinetic (PBPK) model for pulmonary disposition of R6G
developed by Audi et al (Audi et al., 2020). This time point (48 hours) was chosen since it
is clinically early in the pathogenesis of hyperoxia-induced ALI.
Aim # 2: Assess the ability of the ubiquinone analog duroquinone (DQ) to reverse
hyperoxia-induced depolarization of ΔΨm. For this aim, DQ will be added to the perfusate
during the three phases of the experimental protocol under Aim 1 in lungs from rats
exposed to > 95% O2 (hyperoxia) or room air (normoxia) for 48 hours. ΔΨm in mV will be
estimated from the resulting dynamic R6G venous effluent concentrations using a PKPD
model for pulmonary disposition of R6G developed by Audi et al (Audi et al., 2020).
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CHAPTER 2: EXPERIMENTAL METHODS
2.1 Materials
Rhodamine-6G (R6G), verapamil hydrochloride, carbonyl cyanide 4
(trifluoromethoxy) phenylhydrazone (FCCP), duroquinone (DQ), rotenone, glutathione
(GSH) and all other reagents used in experiments were purchased from Sigma-Aldrich.
2.2 Hyperoxic Exposure
Adult male Sprague Dawley rats were used for this study. For hyperoxic rats
(male Sprague-Dawley rats 336.4 ± 10.15 g, n = 9), the rats were placed in a sealed
Plexiglas chamber (13W x 23L x 12H inches) and exposed to >95% O2 (hyperoxia) for
48 hours with access to food and water. The temperature inside the chamber was
maintained at 20°-22°C. Their pre- and post-body weights were recorded as an index of
overall health. For the normoxic lung studies, age-matched control rats (male SpragueDawley rats, 343.7 ± 20.04 g, n = 22) were exposed to room air (normoxia) for 48 hours.
The protocol was approved by the Institutional Animal Care and Use Committees of the
Zablocki Veterans Affairs Medical Center and Marquette University (Milwaukee, WI).
2.3 Isolated Perfused Rat Lung Preparation
Each rat was anesthetized with ketamine/xylazine (ketamine 80-100 mg/kg and
xylazine 10mg/kg, IP), the trachea was clamped, and the chest was opened. Heparin (0.7
IU/g body wt.) was injected in the right ventricle and cannulas were placed through the
pulmonary artery, the pulmonary vein via the left atrium, and the trachea. The lungs were
removed and attached to a ventilation-perfusion system as shown in Figure 4. The
ventilation-perfusion system is connected to pressure transducers for continuous
monitoring of the airway and arterial pressure. The level of the left atrium was used as the
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reference for the pulmonary arterial pressure and the venous effluent pressure was
maintained at the atmospheric pressure. The lungs were perfused with Krebs-Ringer
bicarbonate perfusate (control perfusate) containing (in mM) 4.7 KCl, 2.51 CaCl2, 1.19
MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, and 5.5 glucose along with 0.5% bovine
serum albumin (BSA) and 2.5% Ficoll to maintain consistent oncotic pressure (Audi et al.,
2020). The lungs were ventilated at 40 breaths/min with 15% O2, 6% CO2, balance N2 gas
mixture with end-inspiratory and end-expiratory pressures of approximately 6 and 3
mmHg, respectively.
The control perfusate was used to prime (Masterflex roller pump) the single-pass
perfusion system and ensure that the venous effluent was free of blood. The temperature
was maintained at 37oC and equilibrated with 15% O2, 6% CO2, balance N2 resulting in
perfusate PO2, PCO2 and pH of ~105 Torr, 40 Torr, and 7.4, respectively.
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Figure 5: Schematic diagram of ventilation-perfusion system for Isolated perfused Rat
lungs (Cammarata, 2019)
2.4 Experimental protocol to measure ΔΨm
The protocol to measure ΔΨm in intact lungs was developed by Audi et al. (Audi
et al., 2020). It consists of three phases, a loading phase where the lungs are perfused
with perfusate containing R6G (0.25 µM) and the multi-drug efflux pump P-glycoprotein
(Pgp) inhibitor verapamil (100 µM), a washing phase where the lungs are perfused with
perfusate containing verapamil but without R6G, and an uncoupling phase where the
lungs are perfused with perfusate containing the uncoupler FCCP with verapamil but no
R6G. Pgp pumps R6G from the cytoplasm into the surrounding medium and therefore,
verapamil inhibits the pumping of the rhodamine dye from the Pgp pump. Prior to each
phase, the flow was stopped, and the reservoir emptied and then refilled with the prior
perfusate. A reservoir sample was collected prior to restarting the flow. For the loading
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phase, the lungs were perfused for 10 minutes (single pass) at 10 ml/min during which 2ml venous effluent perfusate sample was collected every 40 seconds during the first 2
minutes and every minute for the remaining 8 minutes. For the washing phase, the lungs
were perfused (single pass) for 5 minutes during which 2-ml venous effluent samples
were collected every minute. For the uncoupling phase, the lungs were perfused (single
pass) for 7 minutes during which 2-ml venous effluent samples were collected every 20
seconds for the first 2 minutes and every minute for the last 5 minutes. All the collected
samples were centrifuged for 1 minute (13,000 g, 4°C) to remove any cellular
components and debris. The sample supernatant was then transferred to plastic cuvettes
to measure R6G emission fluorescence using the PTI system at an excitation signal of
525 nm and emission signal of 565nm (see Appendix for PTI system setup). The R6G
emission signal was then converted to R6G venous effluent concentration using a
standard curve as described below (Audi et al., 2020). At the end of each experiment, the
lungs were weighed, dried, and reweighed to obtain the lung wet to dry weight ratio.
2.4.1 Effect of Hyperoxia on Lung R6G Uptake and Tissue ΔΨm
To assess ΔΨm in hyperoxia-induced lungs from rats (>95% O2 for 48 hours), the
above protocol was carried out in lungs from hyperoxic rats.
2.4.2 Effect of Rotenone on R6G lung Uptake and Lung ΔΨm
To assess the ability of the above protocol to detect ΔΨm depolarization due to a
decrease in complex I activity (positive control), experiments were carried out in lungs
from normoxic rats for which mitochondrial complex I was inhibited by adding rotenone
(complex I inhibitor, 40 µM) along with verapamil to the perfusate for all three phases.
2.4.3 Ability of DQ to Revere Rotenone-induced Changes in Lung R6G Uptake and
Lung Tissue ΔΨm in Lungs from Normoxic Rats
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To assess the ability of DQ to reverse ΔΨm depolarization caused by inhibition of
complex I, the above protocol was repeated in normoxic lungs perfused with both
rotenone (40µM) and DQ (100 µM) added to the perfusate along with verapamil for all
three phases.
DQ can potentially undergo a one-electron reduction to durosemiquinone on
passage through the pulmonary circulation (Audi et al., 2003)(Merker et al., 2004), which
in turn auto-oxidizes to generate hydrogen peroxide (H2O2) or disproportionate to DQH2
and DQ (Merker et al., 2004). To counter the potential pro-oxidant effects of
durosemiquinone, we repeated the protocol in a separate group of normoxic lungs (n = 7)
with rotenone, glutathione (GSH, 16 µM)(Adams et al., 1983), and either DQ or its
vehicle (DMSO) added to the perfusate for all three phases. The concentration of GSH
used is equal to the arterial plasma GSH concentration in rats (Adams et al., 1983).
2.4.4 Ability of DQ to Reverse Hyperoxia-induced Changes in Lung R6g Uptake and
lung ΔΨm depolarization
To assess the ability of DQ to reverse hyperoxia-induced ΔΨm depolarization, the above
protocol was repeated in hyperoxic lungs perfused DQ (100 µM) and GSH (16 µM)
added to the perfusate along with verapamil for all 3 phases.
2.4.5 Effect of DQ vehicle (DMSO) on ΔΨm depolarization in rotenone-induced lungs
from rats
To assess the effect of DQ vehicle (DMSO) on rotenone-induced R6G pulmonary
disposition and ΔΨm depolarization, the above protocol was repeated in lungs perfused with
perfusate containing rotenone and the DQ vehicle (DMSO). The protocol was then repeated
with rotenone and DMSO add to perfusate for all three phases.
2.4.6 Data Analysis
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The dynamic R6G emission fluorescent data obtained from the PTI Felix software
was exported to Excel, where the data was averaged for each time sample for a period of
10 seconds and the slope from the standard curve was used to convert the R6G intensity to
concentration.
2.4.7 Statistical Analysis
Statistical analysis was performed using SigmaPlot version 12.0 (Systat Software
Inc., San Jose, CA). The values between two data sets were compared using unpaired ttest analysis. The statistical significance was set at p < 0.05.
2.5 Standard curve
For each experimental day, a proper standard curve was obtained and used to
convert the R6G emission data from the collected lung samples to concentration (µM).
Known concentrations of R6G dye (0µM, 0.03µM, 0.06µM, 0.125µM, 0.25µM and
0.5µM) were prepared. Each sample was treated the same as a lung sample, i.e.,
centrifuged (13,000 g, 4°C) for 1 minute and transferred to a cuvette, after which its 565
nm emission signal was measured with 525 nm excitation wavelength. The slope of the
emission signal versus R6G concentration curve was estimated and used to convert the
565 nm emission signals of lung samples to concentrations. Standard curves were
obtained with perfusate containing in addition to R6G and verapamil, DQ, rotenone
and/or their vehicles depending on the experimental protocol.
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CHAPTER 3: EXPERIMENTAL RESULTS
3.1 Rat treatments, body weights, lungs wet and dry weights, lungs wet/dry weight
Type

Treatment

Normoxia
(n=4)
Hyperoxia
(n=5)
Normoxia
(n=4)

Verapamil
Verapamil
Verapamil
+ Rotenone

Normoxia Verapamil
(n=4)
+ Rotenone
+ DQ
Normoxia Verapamil
(n=4)
+ Rotenone
+ DQ
+ GSH
Hyperoxia Verapamil
(n=4)
+DQ
+ GSH
Normoxia Verapamil
(n=3)
+ Rotenone
+ DMSO
Normoxia Verapamil
(n=3)
+ Rotenone
+ GSH
+ DMSO

Body
weight
(g)
338 ±
10
329 ±
5
348 ±
16

Wet
Weight
(g)
1.30 ±
0.05
1.58 ±
0.06*
1.22 ±
0.05

Dry
Weight
(g)
0.218 ±
0.008
0.261±
0.007*
0.214 ±
0.009

Wet/dry
weight
ratio
5.98 ±
0.24
6.07 ±
0.14
5.73 ±
0.05

Arterial
pressure
(Torr)
4.5 ±
0.23
4.40 ±
0.65
4.38 ±
0.19

351 ±
9

1.47 ±
0.12

0.237 ±
0.012

6.15 ±
0.24

5.88 ±
0.63

343 ±
9

1.23 ±
0.06

0.213 ±
0.008

5.78 ±
0.08

5.63 ±
0.42

329 ±
6

1.56 ±
0.09*

0.251 ±
0.007*

6.23 ±
0.16

4.38 ±
0.30

343 ±
9

1.29 ±
0.03

0.230 ±
0.006

5.62 ±
0.04

5.67 ±
0.44

329 ±
10

1.33 ±
0.04

0.230 ±
0.003

5.72 ±
0.09

5.16 ±
0.72

Table 1: Rat treatment, body weight, lung wet and dry weight, and wet/dry weight ratio,
and pulmonary artery pressure for flow rate of 10ml/min. Values are mean ± SE. *
significantly different from normoxia.
Hyperoxic rats lost ~ 2% of body weight during the 48-hr exposure period (from
336 ± 3 g to 329 ± 4 g). Table 1 shows rat body weights, lung wet and dry weights, and
wet-to-dry weights along with pulmonary artery pressures for each of the experimental
conditions studied. Two-tailed t-test analysis between the normoxic and hyperoxic lungs,
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(without and with DQ) showed a significant difference in the wet weights (unpaired ttest, p = 0.0085 without DQ and p = 0.047 with DQ) and the dry weights (unpaired t-test,
p = 0.0067 without DQ and p = 0.027 with DQ). Exposure to hyperoxia increased lung
wet weight by ~22% (1.58 ± 0.14, n = 9) compared to normoxic lungs (1.3 ± 0.14, n =
22), with no effect on lung wet/dry weight ratio. These observations are consistent with
previously published data and the hyperoxia-induced increase in lung wet weight being
mainly due to cellular infiltration rather than edema. The addition of DQ and GSH to
perfusate had no significant effect on the lung wet weight, wet/dry weight ratio, or
pulmonary artery pressure of hyperoxic lungs. There was no difference in pulmonary
artery pressure between normoxic and hyperoxia lungs.
Statistical analysis (unpaired t-test) between the normoxic lungs and rotenoneinduced lungs (without DQ) indicated no significant difference in the wet weight (p =
0.3), dry weight (p = 0.72), wet/dry weight (p = 0.3) and the arterial pressure (p = 0.21).
Statistical analysis (unpaired t-test) performed between the normoxic lungs and
rotenone-induced lungs with DQ indicated no significant difference in the wet weight (p
= 0.29), dry weight (p = 0.24), wet/dry weight (p = 0.29) and the arterial pressure (p =
0.06).
Statistical analysis (unpaired t-test) was performed between the normoxic lungs
and rotenone-induced lungs treated with DQ+GSH. Results showed no significant effect
on the lung wet weight (p = 0.37), dry weight (p = 0.67) wet/dry weight ratio (p = 0.46),
or pulmonary artery pressure (p = 0.51) due to the addition of GSH.
Statistical analysis (unpaired t-test) between the rotenone-induced group and the
lungs treated with rotenone + DMSO (with and without GSH) showed no difference in
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lung wet weight (p = 0.13 with GSH and p = 0.33 without GSH), lung dry weight (p =
0.13 with GSH and p = 0.21 without GSH), wet-to-dry weight ratio (p = 0.91 with GSH
and p = 0.14 without GSH), or pulmonary artery pressure (p = 0.51with GSH and p =
0.07 without GSH).
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3.2 R6G Standard curve from various treatments protocols

Figure 6: Treatments standard curve (A) R6G + verapamil. (B) R6G + verapamil + DQ
+ GSH (C) R6G + verapamil + rotenone (D) R6G + verapamil + rotenone + DQ
(E)R6G + verapamil + DQ + GSH (F) R6G + verapamil+ rotenone + DQ vehicle
(DMSO) (G) R6G + verapamil+ rotenone + DQ vehicle (DMSO) + GSH.
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For a given day, a standard curve was obtained under the same experimental
conditions for that day and was used to convert the R6G emission signal to R6G
concentration in the recirculating perfusate. Figure 5 shows standard curves with (A)
verapamil, (B) verapamil + rotenone, (C) verapamil + rotenone +DQ, (D) verapamil +
rotenone + DQ + GSH, (E) verapamil + DQ + GSH (F) verapamil + rotenone + DQ
vehicle (DMSO) and (G) verapamil + rotenone + GSH + DQ vehicle (DMSO) added to
the standard perfusate samples.
For each of the R6G experimental protocols, the raw fluorescent intensity, in
counts per second, was determined by averaging the intensity measurement values
obtained for a period of 10 seconds. The sample containing only the perfusate without
R6G was considered as background and the intensity value from this sample was
subtracted from the intensity from all R6G concentrations. The averaged values were
plotted against the known R6G concentrations. The slope was then used to convert the
intensity of the R6G fluorescence to R6G concentration.
3.3 Lung uptake of R6G in normoxic and hyperoxic lungs during the three phases of
the experimental protocol

30

Figure 7: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase in normoxia (n=5) and hyperoxia(n=5). Values are
mean ± SE
Figure 7 shows the lung uptake of R6G in normoxic (n=5) and hyperoxic (n=5)
lungs. For both lungs, the increase in the venous effluent R6G concentration during the
uncoupling phase is consistent with the uncoupling of lung tissue mitochondria and the
release of R6G that accumulated in the mitochondria during the loading phase, driven by
Δym. Figure 7 shows that for hyperoxic lungs, R6G venous effluent concentrations
tended to be higher during the loading phase, but significantly lower during the
uncoupling phase compared to normoxic lungs. These results are consistent with less
uptake of R6G by hyperoxic lungs due to partial depolarization of Δym.
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3.4 Effect of mitochondrial complex I inhibitor, rotenone on R6G uptake in
normoxic lungs

Figure 8: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase in normoxia (n=5) and rotenone-treated lungs (n=5).
Values are mean ± SE.
Figure 8 shows R6G venous effluent concentration from normoxic lungs without
(n=5) and with rotenone (n=4) added to the perfusate to inhibit complex I. The data
shown that inhibiting complex I significantly increased R6G venous effluent
concentration during the loading phase and washing phase, but significantly decreased it
during the uncoupling phase. These results are consistent with a decrease in R6G lung
uptake due to rotenone-induced Δym depolarization.
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3.5 Effect of DQ and its vehicle (DMSO) on R6G lung uptake in the presence of
rotenone

Figure 9: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase in normoxia (n=5), rotenone-induced lungs (n=4) and
DQ treatment in rotenone induced lungs (with and without GSH, n=4). Values are mean
± SE
.
The results in Figure 9 show that adding DQ to lung perfusate fully reversed
rotenone-induced changes in R6G venous effluent concentration during all three phases.
These results are consistent with the ability of lungs to reduce DQ to DQH2 which in turn
bypasses complex I and reduces cytochrome C at complex III and hence restores lung
rotenone-induced Δym depolarization.
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To reduce the potential of pro-oxidant effect of adding DQ to the lung perfusate,
we repeated the experiments with both DQ and GSH (16µM) added to the perfusate for
all three phases. Addition of GSH (n=4) did not affect the ability of DQ to fully reverse
the effects of rotenone on R6G venous effluent concentration during all three phases of
the protocol.

Figure 10: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase in normoxic lungs without (n=5) or with rotenone
(n=4) and rotenone + DQ vehicle (DMSO) +GSH (n= 3), or rotenone +DMSO + GSH
(n=3) added to the lung perfusate. Values are mean ± SE.
The vehicle for rotenone and DQ is DMSO. To assess the effect of the DQ vehicle
on lung R6G uptake, experiments were repeated in normoxic lungs with rotenone and DQ
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vehicle (DMSO) with and without GSH (n=3 for each protocol) added to the perfusate.
Figure 10 shows that DMSO, without or with GSH, had no effect on the rotenoneinduced changes in R6G venous effluent concentrations during the three phases of the
protocol.
3.6 Effect of Duroquinone on R6G lung uptake in hyperoxia-treated lungs from rats

Figure 11: Solid symbols: R6G venous effluent concentrations during the loading phase,
wash phase, and uncoupling phase in normoxic lungs (n=5), hyperoxic lungs (n=5), and
hyperoxic lungs with DQ added to the perfusate (n=4). Values are mean ± SE.
To assess the efficacy of DQ to reverse hyperoxia-induced changes in R6G
venous effluent concentration during the loading and uncoupling phases, we repeated the
protocol in hyperoxic lungs with DQ added to the perfusate. As seen in Figure 11,
addition of DQ to perfusate fully reversed hyperoxia-induced changes in R6G venous
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effluent concentration during the loading and uncoupling phases consistent with the
ability of DQ to overcome hyperoxia-induced decreases in complexes I and II activities
by its reduction to DQH2 which in turn bypasses complexes I and II, reduces cytochrome
c at complex III and reverses hyperoxia-induced partial Δym depolarization. Again, GSH
was also added to the perfusate along with DQ to mitigate the potential pro-oxidant
effects of durosemiquinone.
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Chapter 4: Computational Model for Quantitative Interpretation of
R6G dynamic Data and Estimation of Lung Tissue ΔΨm
4.1 Pharmacokinetic model for the disposition of R6G through the lungs
For quantitative interpretation of the R6G dynamic data, Audi et al. developed a
physiologically based pharmacokinetic (PBPK) model for the disposition of R6G on
passage through the pulmonary circulation. The model accounts for the dominant
processes that determine the lung uptake of R6G on passage through the pulmonary
circulation, including ΔΨm (Audi et al., 2020).

Figure 12:Pharmacokinetic model of the uptake and retention of R6G in the lungs (Audi
et al., 2020). See glossary for definitions of the different symbols
The model consists of four regions namely the tubing region, the lung vascular
region, the extravascular region, and the mitochondrial region, with volumes (in ml) Vtub,
Vc, Ve, and Vm, respectively. The model accounts for the dominant processes that
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determine the mitochondrial uptake and retention of R6G in the lungs. Kd1 is the
dissociation equilibrium constant for the binding of R6G to BSA in the lung vascular
region and is assumed to be a rapidly equilibrating process. From the vascular region,
R6G passes to the extravascular region and from the extravascular region to the
mitochondrial region driven by electrochemical gradients. The model uses a modified
one-dimensional Goldman-Hodgkin-Katz equation to account for the R6G flux across the
plasma membrane (J1) and inner mitochondrial membrane (J2) (Audi et al., 2020).
The model also accounts for the P-glycoprotein pump, which is a multi-drug
efflux pump for the rhodamine dyes from the extravascular region to the vascular region.
Kd3 is the dissociation equilibrium constant for the binding of R6G to various proteins in
the mitochondrial region and is assumed to be a rapidly equilibrating process. The
differential equations that describe the rates of change of R6G concentration within each
region were derived using the law of mass balance and mass action.
4.2 Derivations of model equations, model parameters
4.2.1 Glossary (Audi et al., 2020) :
[Be]

Concentration of extravascular R6G binding sites (µM)

[Bc] = [BSA]

Vascular BSA concentration (%BSA)

[Bm]

Concentration of mitochondrial R6G binding sites (µM)

[Ctub]

Free R6G concentration within the tubing region (µM)

[Ce]

Free R6G concentration within the extravascular region (µM)

[CeBe]

Concentration of bound R6G within the extravascular region (µM)

[Cc]

Free R6G concentration within the vascular region (µM)

[CcBc]

Concentration of bound R6G within the vascular region (µM)
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[𝐶

Total concentration of R6G within the vascular region (µM)

[Cin]

Infused R6G concentration (µM)

[Cm]

Free R6G concentration within the mitochondrial region (µM)

[CmBm]

Concentration of bound R6G within the mitochondrial region (µM)

Q

Flow rate (ml/min)

J1

Dye flux across plasma membrane (nmol/(cm2.min))

J2

Dye flux across inner mitochondrial membrane (nmol/(cm2.min))

k1

Association rate constant of R6G - BSA binding in the vascular
region (%BSA-1.min-1)

k-1

Dissociation rate constant of R6G-BSA binding within the vascular
region (min-1)

k2

Association rate constant of R6G – Be binding in the extravascular
region (µM-1.min-1)

k-2

Dissociation rate constant of R6G – Be binding in the extravascular
region (min-1)

k3

Association rate constant of R6G - Bm binding in mitochondrial
region (µM-1.min-1)

k-3

Dissociation rate constant of R6G - Bm binding in mitochondrial
region (min-1)

Kd1 = k-1/k1

Dissociation equilibrium constant for R6G - BSA binding in
vascular region (umol-1 x min-1)

Kd3 = k-3/𝑘̅3

Dissociation equilibrium constant for R6G - Bm binding in the
mitochondrial region
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𝑘̅2 = k2[Be]

Apparent rate constant for R6G – Be binding in the extravascular
region (min-1)

𝑘̅3 = k3[Bm]

Apparent rate constant for R6G - Bm binding in the mitochondrial
region (min-1)

Kpgp

Rate of efflux of R6G via Pgp pump from extravascular to vascular
region (ml/min)

P1

R6G permeability across plasma membrane (cm/min)

P2

R6G permeability across mitochondrial membrane (cm/min)

S1

Surface area of plasma membrane (cm2)

S2

Surface area of mitochondrial membrane (cm2)

V3

Apparent volume of mitochondrial region (ml)

Vtub

Physical volume of tubing region (ml)

Ve

Physical volume of extravascular region (ml)

Vc

Physical volume of vascular region (ml)

Vm

Physical volume of mitochondrial region = 0.02 x Ve (ml)

α = ZF/RT

0.0374 mV-1 at 37ºC is a constant dependent on the universal gas
constant (R), Faraday constant (F), R6G valence (Z), and absolute
temperature (T)

ΔΨm

Mitochondrial membrane potential (mV)

ΔΨp

Plasma membrane potential (mV)

4.2.2 Governing model differential equations
Tubing Region
"[$!"# ]
"&

=(

'
!"#

([𝐶)* ] − [𝐶&+, ])

(1)
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where [Cin] and [Ctub] are total (free + bound) concentration of R6G in reservoir and tubing
regions, respectively.
Vascular region
Rates of change in the concentrations of free, [Cc], and BSA-bound, [CcBc], R6G within the
vascular region:
𝑉!

"[$! ]
"&

= 𝑉! (𝑘'( [𝐶! 𝐵! ] − 𝑘( [𝐶! ][𝐵! ]) − 𝑆( 𝐽( + 𝐾)*) [𝐶+ ] + 𝑄[1[𝐶&,- ]. − [𝐶! 2)

(2)

The left side of the equation indicates the rate of change of free R6G concentration in the vascular
region. The terms on the right side of the equation respectively account for binding and unbinding
of R6G with bovine serum albumin in vascular region, R6G diffusion between vascular and
extravascular regions driven by an electrochemical gradient, Pgp-mediated R6G efflux from the
extravascular region back to vascular region, and R6G convective mass flux.

𝑉!

"[$$ -$ ]
"&

= 𝑉! (𝑘. [𝐶! ][𝐵! ] − 𝑘/. [𝐶! 𝐵! ]) + 𝑄[([𝐶&+, ], − [𝐶! 𝐵! ])

(3)

where Bc = perfusate % BSA, and [Ctub]f and [Ctub]b are the free and BSA bound R6G
concentrations in the tubing region such that,

[𝐶&+, ] = [𝐶&+, ]0 + [𝐶&+, ],

(4)

and
𝐽. =

/12% ∆4&
(6 '(∆*& /.)

1𝑒 /1∆4& [𝐶! ] − [𝐶6 ]3

(5)

Assuming rapidly equilibrating interactions between R6G and perfusate BSA then,

𝑘. [𝐶! 𝐵! ] = 𝑘. [𝐶! ][𝐵! ]
[𝐶! 𝐵! ] =

8%
8'%

[𝐶! ][𝐵! ] =

(6)
[$$ ][-$ ]

(7)

9+%

where Kd1 is the R6G to BSA binding equilibrium dissociation rate constant. Let

"""! ] = [𝐶! ] + [𝐶! 𝐵! ] = [𝐶! ] 41 +
[𝐶

[-$ ]
9+%

6

(8)
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then addition of equations (2) and (3) after substituting equations (7) and (8) for free and
bound forms of R6G in the vascular region results in:

𝑉!

"[$$̅ ]
"&

"""! 9)
= −𝑆. 𝐽. + 𝐾;<; [𝐶6 ] + 𝑄[1[𝐶&+, ] − [𝐶

(9)

and
𝐽. =

/12% ∆4&
(6

'(∆*&

/.)

:𝑒 /1∆4&

===$ ]
[$
[- ]
.? $

− [𝐶6 ];

(10)

/+%

Extravascular region
Rates of change in the concentrations of free, [Ce], and protein-bound, [CeBe], R6G within
this region:

𝑉6

"[$0 ]

𝑉6

"[$0 -0 ]

"&

= 𝑉6 (𝑘/@ [𝐶6 𝐵6 ] − """
𝑘@ [𝐶6 ]) − 𝑆@ 𝐽@ + 𝑆. 𝐽. − 𝐾;<; [𝐶6 ]

"&

"""@ [𝐶6 ])
= 𝑉6 − (𝑘/@ [𝐶6 𝐵6 ] + 𝑘

(11)
(12)

""""
where [𝑘
@ ] = 𝑘@ [𝐵6 ] and
/12 ∆4

1
2
(𝑒 /1∆42 [𝐶6 ] − [𝐶A ])
𝐽@ = (6 '(∆*
2 /.)

(13)

Mitochondrial Region
Rates of change in the concentrations of free, [Cm], and protein-bound, [CmBm], R6G within
this region:

𝑉A

"[$2 ]

𝑉A

"[$2 -2 ]

"&

= 𝑉A (𝑘/B [𝐶A 𝐵A ] − 𝑘B [𝐶A ][𝐵A ]) + 𝑆@ 𝐽@

"&

= 𝑉A (−𝑘/B [𝐶A 𝐵A ] + 𝑘B [𝐶A ][𝐵A ])

(14)
(15)

where [Bm] = protein concentration within mitochondrial region
Assuming rapidly equilibrating interactions between R6G and Bm then:

𝑘/B [𝐶A 𝐵A ] = 𝑘B [𝐶A ][𝐵A ]
[𝐶A 𝐵A ] =

[$2 ]
9+3

(16)
(17)
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Where 𝐾"B =

8'3
83 [-2 ]

is R6G and Bm binding equilibrium dissociation constant.

The addition of equations (14) and (15) after substituting equation (17) for [CmBm] results in
.

𝑉A 41 + 9 6
+3

"[$2 ]
"&

= 𝑉B

"[$2 ]
"&

.

𝑤ℎ𝑒𝑟𝑒 𝑉B = 𝑉A 41 + 9 6
+3

= 𝑆@ 𝐽@

(18)

is the apparent volume of the mitochondrial extravascular

region.
The total R6G concentration at time t in the tubing and vascular region are
[Ctub](t) and [𝐶!̅ ](t), respectively. [Ce](t) and [Cm](t) refer to the free R6G concentrations
in the extravascular and mitochondrial regions at time t, respectively. The bound R6G
concentration at time t in the extravascular region is [CeBe](t). The initial R6G
concentration in the reservoir is [Cin]. The % BSA in the perfusate is [Bc]. The
concentration of R6G in the binding sites in the mitochondria is [Bm]. The pump flow is
depicted as Q (ml/min). The product of the permeability of R6G across the plasma and
the mitochondrial membranes and the surface area (S) of these membranes are P1S1
(ml/min) and P2S2 (ml/min), respectively.
Kpgp (ml/min) represent the Pgp-mediated R6G efflux rate from extravascular to
vascular region. The dissociation equilibrium constant for R6G-BSA binding in the
vascular region is K ". =

C'%
C%

. The dissociation equilibrium constant for R6G-Bm binding

in the mitochondrial region is K "B =

C'3
C3 [-2 ]

. The apparent volume (ml) in the

.

mitochondrial region is 𝑉B = 𝑉A 41 + 8 6 . The constant α = ZF/RT is dependent on the
+3

gas constant ®, Faraday constant (F), R6G valence (+1), and absolute temperature and is
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equal to 0.0374 mV-1 at 37°C. The mitochondrial and plasma membrane potential are
ΔΨm and ΔΨp, respectively.
The model-governing ODEs were solved numerically using the MATLAB
(MathWorks) function “ode45”, which is based on an explicit Runge-Kutta formula.
4.3 Estimation of Model parameters
Parameter

Description

Unit

"""@
𝑘

Apparent rate constant for R6G – Be binding in the
extravascular region

(min-1)

𝑘@

Dissociation rate constant of R6G – Be binding in the
extravascular region

(min-1)

𝐾"B

Dissociation equilibrium constant for R6G - Bm binding
in the mitochondrial region

𝑃. 𝑆.

The product of the permeability of R6G across the plasma
membrane and the surface area (S)

ml/min

𝛥𝛹A

Mitochondrial membrane potential

mV

Table 2: Unknow model parameters
To reduce the number of unknown model parameters, the lung vascular volume
(Vc = 0.85 ml) and the lung extravascular volume (Ve = 1.0 ml) (Audi, et al., 2003) were
set to constant values. To break the correlation between Vm and ΔΨm, the ratio Vm/Ve was
set to 0.02 (Gan et al., 2011). To break the correlation between P1S1 and ΔΨp, the value of
ΔΨp was set to -43mV (Gan et al., 2011). To break the correlation between Kd1 (0.32%)
and ΔΨm, and between P2S2 (1.12 ml/min) and ΔΨm, the values of Kd1 and P2S2 were set
to previously estimated values (Audi et al., 2020). Verapamil (100 µM) was assumed to
completely inhibit Pgp. As such, Kpgp was set at 0. Thus, the unknown model parameters
"""@ , k-2 and P1S1 (Table 2).
are ΔΨm, Kd3, 𝑘
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The differential equations were solved using the MATLAB (MathWorks)
function “ode45”. The equations were solved with the following initial conditions (t = 0):
"""! ](0) = [Ce](0) = [Cm](0) = 0 µM and [Ctub](0) = [Cin] for the loading phase, and
[𝐶
[Ctub](0) = 0 for the washing and uncoupling phases. (Audi et al., 2020)
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Chapter 5: Modeling results
5.1 Estimation of model parameters
The model solution was fit to each data set using the MATLAB function
“lsqcurvefit”, which implements a non-linear regression algorithm. The estimated values
of model parameters and representative model fits to data are shown in Table 3 and
Figures 12-19.
P1S1
(ml/min)
Normoxia (n=5)
46.98 ±
0.67
Hyperoxia (n=5)
48.09 ±
0.80
Normoxia + Rotenone
50.12 ±
(n=4)
0.88
Normoxia + Rotenone
46.82 ±
+ DQ (n=4)
0.62
Normoxia + Rotenone
47.58 ±
+ DQ + GSH (n=4)
0.48
Hyperoxia + DQ +
46.62 ±
GSH (n=4)
0.73
Normoxia + Rotenone
50.65 ±
+ DMSO (n=3)
0.87
Normoxia +Rotenone + 49.32 ±
DMSO + GSH (n=3)
0.79

"""
𝒌𝟐
(ml/min)
9.59 ±
1.79
7.43 ±
1.25
4.66 ±
0.39*
9.78 ±
1.54
8.09 ±
1.34
10.62 ±
2.22
4.65 ±
0.58*
5.69 ±
1.65

k-2
(min-1)
0.113 ±
0.018
0.058 ±
0.013*
0.065 ±
0.009
0.106 ±
0.012
0.127 ±
0.026
0.097 ±
0.015
0.069 ±
0.007
0.075 ±
0.0048

Kd3
0.0136 ±
0.0008
0.0094 ±
0.0004*
0.0056 ±
0.0005*
0.0134 ±
0.0004
0.0135 ±
0.0012
0.015 ±
0.0012
0.0045 ±
0.0009*
0.0064 ±
0.0017*

ΔΨm
(mV)
-147.1 ±
13.2
-109.8±
9.3*
-57.3 ±
3.1*
-131.1 ±
16.3
-122.7 ±
5.7
-157.7±
17.2
-62.5 ±
4.1*
-60.4 ±
9.4*

Table 3: Estimated value of model parameters. Values are mean ± SE.*different from
Normoxia (t-test, P < 0.05).
The values of the model parameters were estimated from fitting the mean values
of various parameters in a normoxic and hyperoxic lungs. The estimated values of the
model parameters (Table 3) show that rat exposure to hyperoxia depolarized lung tissue
Δym from -147 mV to -109 mV. Furthermore, exposure to hyperoxia decreased the
values of Kd3 (29%) and k-2 (48%) but had no significant effect on the values of k" @ and
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P1S1. As expected, inhibition of complex I activity with rotenone depolarized Δym from
-147 mV to -57 mV. Furthermore, rotenone decreased the values of k" @ (50%), k-2 (40%),
and Kd3 (60%) compared to values in the absence of rotenone. Lung perfusion with DQ or
DQ + GSH fully reversed the rotenone effect on the values of Δym and other model
parameters. The results suggest that GSH does not influence the pulmonary disposition of
R6G or the ability of DQ to reverse rotenone-induced Δym depolarization. Additional
results show that adding DMSO (DQ vehicle) to the perfusate along with rotenone had no
significant effect on the estimated values of the model parameters. The modeling results
also show that the addition of DQ + GSH to the recirculating perfusate fully reversed
hyperoxia-induced depolarization of Δym and the effect of hyperoxia on the values of Kd3
and k-2.
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Figure 13: Solid symbols: Normoxia R6G venous effluent concentrations (mean ± SE)
during loading, washing and uncoupling phases. Solid line is model fit to data.
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Figure 14: Solid symbols: Hyperoxia R6G venous effluent concentrations (mean ± SE)
during loading, washing and uncoupling phases. Solid line is model fit to data.
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Figure 15: Solid symbols: Rotenone-induced R6G venous effluent concentrations (mean ±
SE) during loading, washing and uncoupling phases. Solid line is model fit to data.
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Figure 16: Solid symbols: Rotenone +DQ R6G venous effluent concentrations (mean ±
SE) during loading, washing and uncoupling phases. Solid line is model fit to data.
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Figure 17: Solid symbols: Rotenone +DQ+GSH R6G venous effluent concentrations
(mean ± SE) during loading, washing and uncoupling phases. Solid line is model fit to
data.
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Figure 18: Solid symbols: Hyperoxia + DQ+ GSH R6G venous effluent concentrations
(mean ± SE) during loading, washing and uncoupling phases. Solid line is model fit to
data.
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Figure 19: Solid symbols: Rotenone + DQ vehicle(DMSO) R6G venous effluent
concentrations (mean ± SE) during loading, washing and uncoupling phases. Solid line is
model fit to data
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Figure 20: Solid symbols: Rotenone + DQ vehicle (DMSO)+GSH R6G venous effluent
concentrations (mean ± SE) during loading, washing and uncoupling phases. Solid line is
model fit to data.
5.2 Correlation matrix
Table 4 shows measures of precision and estimability of model parameters,
including 95% confidence interval and correlation matrix.
The correlation matrix provides a measure of interdependence between a given
parameter and each of the others. For the correlation matrix, the ijth entry of the
correlation matrix is the correlation coefficient between the ith and jth model parameters.
The values closer to 0 indicate that the parameters are not correlated, and the values
closer to 1 and -1 indicate that the parameters are correlated.
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Table 4 shows that for R6G dynamic data from both normoxic and hyperoxic
lungs, the correlation coefficients between model parameters are also relatively small.
A correlation coefficient of 1 means that for a change in one variable can be completely
compensate for by a change in another parameter. As such, the two parameters are
completely dependent and cannot be independently identified or estimated.
For a given parameter, the 95% confidence interval represents the range of values
for the model parameter that provide a similar fit of the model to data. The wider the 95%
confidence interval, the less confidence you have in the estimated value of the model
parameter.
The correlation coefficients and 95% confidence intervals were estimated using
the following equation.
Correlation Coefficient: For a model with P parameters, the correlation matrix, CC, is a
P x P matrix obtained as follows:
–1

CC ij =

XTX ij
T

X X

–1
ii

T

X X

–1

, i = 1, …, P and j = 1, …, P

jj

where X is the Jacobian matrix. It is an N x P matrix, where N is the number of data
points. In the above equation, CCij = CCji = correlation coefficient between the ith and jth
parameters (i ¹ j).
Confidence Interval: For a model with N parameters, the 100 (1- a) % asymptotic
confidence intervals, i.e. 100(1- a) % chance that the interval contains the true value of
the model parameter that best fit model to data, can be estimated using the following
equation.

b j ± Se b j t N – P; a
2
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where bj is the value of the jth model parameter that best fit model to data, N is the
number of data points, t N – P; a is the upper a/2 quantile for student t-distribution

2

with

N – P degrees of freedom, and Se(bj) is the standard error of the jth parameter bj.

X TX

Se b j = s
where X is the Jacobian matrix and
the matrix

X TX

–1

X TX

–1

–1
jj

is equal to the jth diagonal element of

jj

and s2 = SSD/(N-P) where SSD is the sum of square difference

between data and best model fit to data.

Estimated
Model
Parameters

"""
𝑘@
𝑘/@
𝐾"B
ΔΨA
𝑃. 𝑆.

9.54
0.13
0.0133
-142.95
46.95

"""
𝑘@
𝑘@
𝐾"B
ΔΨA
𝑃. 𝑆.

7.85
0.074
0.0092
-111.43
49.83

Measure of Precision of Model Parameter Estimates
95%
Correlation Matrix
confidence
interval
Normoxic mean R6G data
"""
𝑘/@
𝐾"B
ΔΨA
𝑃. 𝑆.
𝑘@
± 1.67
1
± 0.02
0.66
1
± 0.0008
0.43
0.12
1
± 13.32
0.37
0.44
0.73
1
± 0.82
0.77
0.29
0.43
0.18
1
Hyperoxic mean R6G data
"""
𝑘/@
𝐾"B
ΔΨA
𝑃. 𝑆.
𝑘@
± 1.53
1
± 0.014
0.80
1
± 0.0005
0.56
0.30
1
± 10.88
-0.19
0.09
0.25
1
± 2.22
-0.87
-0.58
-0.59
0.31
1

Table 4: Estimates of model parameters from normoxic and hyperoxic mean R6G data
and measures of precision of these estimates, namely 95% confidence intervals and the
correlation matrix.
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Chapter 6: Discussion, Conclusions & Future Direction
One objective of this thesis was to use a previously developed experimental and
computational approach to assess the effect of rat exposure to hyperoxia on lung tissue
ΔΨm in intact perfused lungs using the lipophilic cationic dye, R6G. The results show that
rat exposure to hyperoxia (>95% O2 for 48 hours) resulted in a partial depolarization (33 mV) of lung Δym. The ability of the experimental-computational approach for
detecting Δym depolarization in isolated perfused rat lungs was assessed in normoxic
lungs perfused with the complex I inhibitor, rotenone, which depolarized lung tissue Δym
from – 147 mV to - 57 mV, a -90 mV depolarization. Another objective was to assess
the ability of duroquinone (DQ) in reversing lung tissue Δym depolarization resulting
from decreases in the activities of mitochondrial complexes I and II. The results show
that DQ was able to fully reverse both rotenone-induced and hyperoxia-induced partial
depolarization of lung tissue Δym. On passages through lungs, DQ is reduced to DQH2,
which in turn bypasses complexes I and II and reduces cytochrome c at complex III and
in the process reverse any depolarization in Δym resulting from a decrease in complex I
activities. To our knowledge, this is the first report of measuring the ΔΨm depolarization
in hyperoxia-induced ALI in intact lungs from rats.
The normal range for ΔΨm in lungs and cultured pulmonary endothelial cells is
between -136 to -150 mV (Gan et al., 2011)(Audi et al., 2020) (Bagkos et al.,
2014)(Alpert et al., 2018). A lower or depolarized value is indicative of mitochondrial
dysfunction(Bhandari et al., 2013). Rat exposure to hyperoxia induces mitochondrial
changes, including decreased lung tissue activities of mitochondrial complexes I and II
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(Sepehr et al., 2013), which in turns causes partial depolarization of lung ΔΨm.
Functional implications of the measured hyperoxia-induced partial depolarization of ΔΨm
in the present study could lower mitochondrial ATP production rate. This is consistent
with results from Audi et al. showing that Dym recovery from ADP-induced
depolarization (state 3) in mitochondria isolated from hyperoxic lungs was substantially
slower than that from normoxic lungs (Audi et al., 2017). Fisher AB reported that rat
exposure to 100% O2 for 48 hours increased lung lactate production rate (78%) and
lactate to pyruvate ratio (105%) as an index of glycolytic ATP production. Fisher AB
also reported an increase in the glycolytic ATP production and the lactate to pyruvate
ratio and concluded that this increase in glycolytic ATP production could compensate for
a decrease in ATP production via mitochondrial oxidative phosphorylation (Fisher &
Beers, 2008). Bassett et al reported an increase in the rate of glucose utilization and an
increase in the rate of lactate + pyruvate production by ~99% in lungs of rats when
exposed to hyperoxia (100% O2 for just 24 hours), consistent with the need of cells to
increase glycolytic ATP production to compensate for decreased ATP production via
mitochondrial oxidative phosphorylation, potentially due to hyperoxia-induced partial
depolarization of lung tissue Dym.(Bassett et al., 1992) These results suggest potentially
significant functional implications for the hyperoxia-induced partial depolarization of
lung tissue Dym measured in the present study.
Previous studies have evaluated the impact of inhibiting mitochondrial complex I
and/or II on mitochondrial bioenergetics and respiration in intact lungs and cultured
endothelial cells, and have assessed the ability of exogenous quinone compounds such as
DQ and CoQ1 to restore the lung/cell bioenergetics and respiration (Audi et al., 2003)
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(Bongard et al., 2013) (Bongard et al., 2015). Audi et al reported that the inhibition of
complex I and II decreased the oxygen consumption by ~60% and that this decrease was
fully reversed by the addition of DQ to the recirculating perfusate (Audi et al., 2003).
These data are consistent with the ability of DQH2 to bypass complexes I and II and
reduce cytochrome c at complex III. Bongard et al. reported that inhibition of complex I
decreased the ATP levels by ~ 60% , and increased lactate/pyruvate ratio by ~ 200%, as
an index of the glycolic pathway and reported that these changes were fully reversed in
the presence of CoQ1 (Bongard et al., 2013). Bongard et al. also assessed the effects of
rotenone on ATP level and Dym in rat pulmonary microvascular endothelial cells in
culture, and on the ability of CoQ1 to reverse those effects (Bongard et al., 2015). They
showed that rotenone decreased ATP by 75%, depolarized Dym from -129 mV to -93
mV, decreased O2 consumption by 85%, and increased cell monolayer permeability and
reported that these effects were completely reversed when COQ1 was present along with
the inhibitor (Bongard et al., 2015). The effect of rotenone on cellular Dym in these
previous studies is consistent with the results in the present study in intact functioning
lungs.
DQ can be reduced to DQH2 as well as durosemiquinone, which auto-oxidize
back to DQ with superoxide as a by-product, which in turn dismutates to form H2O2, or
disproportionate to DQH2 and DQ (Merker et al., 2004)(Audi et al., 2003). Audi et al.
showed that the reduction of DQ is predominantly via NQO1, which is a two-electron
reduction, on passage through the rat and mouse pulmonary circulations (Audi et al.,
2003). For the present study, to counter any potential pro-oxidant effect due to
durosemiquinone, GSH was added along with DQ to the lung perfusate.
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DQH2 can serve as an anti-oxidant by reducing H2O2 to H2O in addition to
reducing complex III (Merker et al., 2004). The addition of GSH alone to the perfusate
did not have an effect on the rotenone-induced Dym depolarization (Figure 9) which
suggests that the ability of DQ to fully reverse rotenone-induced Dym depolarization is
not due to the anti-oxidant effect of DQH2, but rather due to the ability of DQH2 to
bypass complexes I and II and reduce cytochrome c at complex III.
Coenzyme Q10 (CoQ10) is a ubiquinone analog and is widely available over the
counter as a dietary supplement and recommended by primary care providers and
specialists alike (Sood et al., 2021). Previous studies have assessed the effect of CoQ10 on
sepsis-induced acute lung injury (Li et al., 2019). The results showed that CoQ10
increased the survival rate and alleviated pulmonary edema in rats with sepsis-induced
ALI. The ability of CoQ10 to demonstrate some beneficial effect in the treatment of
mitochondrial disease is thought to rely mainly on its ability to restore electron flow in
the mitochondrial respiratory chain and replenish cellular antioxidant capacity
(Neergheen et al., 2017). CoQ10 in patients with mitochondrial disorders have shown to
have an impact on the aerobic capacity in lungs (Sood et al., 2021).
The computational model provides a framework for mechanistic interpretation of
the data and for estimation of the values of parameters descriptive of the dominant
processes determining the R6G uptake by the lung tissue and mitochondria, including the
ΔΨm. For the computational analysis of the R6G data using the PBPK model, the values
of lung vascular volume (Vc = 0.85) and lung extravascular volume (Ve = 1) were fixed to
values estimated form normal rats, and hence were assumed to be unaffected by exposure
to hyperoxia. Crapo et al. showed that rat exposure to 100% O2 for 40 hours had no
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significant effect on lung vascular volume (Crapo et al., 1980). Another study by Block
and Fisher also showed that hyperoxia exposure (100% O2 for 48 hours ) did not affect
the lung vascular flow distribution (Block & Fisher, 1977). Moreover, simulations using
the PBPK model predict that a 15% decrease in vascular volume would result in only a
-2 mV change in the estimated value of Dym.
One of the questions that arises is the effect of hyperoxia on the plasma
membrane potential. For the present study, the value of ΔΨp was fixed to a previously
estimated value (-43mV) and was assumed to be unaffected by exposure to hyperoxia
(Gan et al., 2011). However, ΔΨp could be altered by injury or disease, and model
simulations show that depolarization of ΔΨp could alias for Dym depolarization as far as
changes in dynamic R6G data. However, not much is known about the effect of exposure
to hyperoxia on ΔΨp . Changes in ΔΨp due to hyperoxia could be measured using
fluorescent dyes sensitive to ΔΨp such as the anionic probe bis-oxonol (Landry et eal.,
1991) (al-Mehdi et al., 1997)(Zhang et al., 2005), but such experiments are outside the
scope of the present study. The fact that the addition of DQ to the lung perfusate fully
reversed hyperoxia-induced changes in the R6G concentration data (Figure 10) and in the
estimated values of the model parameters (Table 3), including Dym, suggests that the
assumption of no difference in the values of Δyp (and vascular volume) between
normoxic and hyperoxic lungs is reasonable.
Previous studies have shown that complex I and complex II activity decreases
when exposed to hyperoxia (Sepehr et al., 2013). However, the results from the present
study do not provide information about the individual contributions of hyperoxia-induced
decreases in complex I versus complex II activity to the measured partial depolarization
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of Δym. In the electron transport chain, mitochondrial membrane potential is generated by
pumping electrons from the mitochondrial matrix into the intermembrane space at
complexes I, III and IV. Normally, 10 H+ are pumped via the complex I-III-IV versus 6
H+ via the complex II-III-IV pathway. Based on this, a decrease in complex I would be
expected to have a higher impact on Dym than a decrease in complex II activity.
However, studies by Audi et al. reported that 48% decrease in mitochondrial complex I
activity when exposed to hyperoxia (85% for 48 hours) compared to normoxic lungs did
not produce a detectable change in whole lung O2 consumption rate (Audi et al., 2008).
One possible explanation for this result is that the complex I activity is normally in
excess compared with the rate of electron flow through the respiratory chain. This is
consistent with the results of a study by Barrientos and Moraes, in which the effects of
complex I impairment on cell respiration were evaluated in a rotenone-treated human
osteosarcoma-derived cell line (Barrientos et al., 1999). They showed that complex I
activity was inhibited by as much as 35%, with little effect (5%) on cell respiration.
Another possible explanation could be due to the compensatory mechanism of cells to
sustain cell respiration in complex I impaired hyperoxia-induced lungs.
Rotenone and hyperoxia decreased the values of the model parameters descriptive
of R6G binding (k" @ , k-2, and Kd3) within the non-mitochondrial and mitochondrial
regions. This could be due to the effect of rotenone or hyperoxia on the number of R6G
binding sites within the non-mitochondrial and mitochondrial regions and/or on the R6G
binding kinetics due to changes in the redox states within these regions resulting from the
partial depolarization of Dym (Dell’Antone et al., 1972). The fact that the addition of DQ
to perfusate fully reversed the effects of hyperoxia and rotenone on all model parameters
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(Table 3), including k" @ , k-2, and Kd3, suggests that the changes in these parameters with
rotenone or hyperoxia (Table 3) are likely due to changes in R6G binding kinetics rather
than the number of binding sites. Correlations between k" @ , k-2, and Kd3 and/or between
these parameters and other model parameters (Table 4) could also be a factor.
The present study does not provide direct information about the contribution of
various cell types to changes in R6G lung uptake and the estimated Δym depolarization
due to hyperoxia. The lung consists of 40 different cell types (Dinh et al., 2017)(Kotton
& Morrisey, 2014). However endothelial cells would be expected to dominate because of
their large surface area and high fraction (~50%) of total cells in normal lungs, and their
direct contact with R6G in perfusate (Crapo et al., 1980). Endothelial cells are also
considered as the primary and early target of hyperoxia-induced acute lung injury (Crapo
et al., 1980)(Audi et al., 2005)(Audi et al., 2008)(Gan et al., 2011). Although the question
regarding the contributions of specific cell types to the hyperoxia-induced partial Δym
depolarization will be important for future studies, alteration in the lung R6G uptake and
estimated Δym as an index of pulmonary mitochondrial dysfunction has functional
implications regardless of the lung cell types involved. This could be addressed by
measuring the Δym in isolated epithelium and endothelial cells following exposure of the
cells to hyperoxic conditions.
Increased vascular permeability is a cardinal feature of clinical ALI (Matthay et
al., 2012). Previously, Audi et al. showed that rat exposure to hyperoxia for 48 hours
increased the pulmonary endothelial filtration coefficient, Kf, a sensitive measure of
endothelial barrier function, by ~ 2 fold (Audi et al., 2016). Bongard et al. showed that
inhibiting lung complex I with rotenone, which decreased lung ATP by ~ 60%, increased
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Kf by ~ 2.8 fold, and hence established a connection between mitochondrial bioenergetics
and Kf (Bongard et al., 2013). Furthermore, the addition of the exogenous quinone CoQ1
to the isolated rat lung perfusate fully reversed the effect of rotenone on lung ATP and Kf.
Further studies are needed to assess the effect of DQ in reversing the effect of hyperoxia
on Kf.
Das et al. reported a decrease in the activities of complex I and II in hyperoxiaexposed lung mitochondria. A decrease in complex I and complex II driven oxygen
consumption rate (OCR) was observed due to hyperoxia demonstrating a dysfunction of
complex II in addition to complex I by producing superoxide (Das, 2013). Therefore,
further studies are needed to evaluate the effect of complex I and complex II inhibition to
assess their individual effect on the Δym depolarization.
Several different animal models have been used to study acute lung injury, yet
there are important and sometimes major differences among animal models in responses
to injury. Hyperoxia has been used as a direct and as a secondary injury in animal studies
to assess the effect of hyperoxia on mitochondrial bioenergetics.(Matute-Bello et al.,
2008) This approach could be utilized in future studies for evaluating the effect of various
other models of ALI (eg. LPS treatment, oleic acid) on Δym in intact lungs to determine if
this is a common pathway for the pathogenesis of ALI.
In conclusion, this thesis demonstrates our ability to detect and quantify
hyperoxia-induced Δym depolarization in intact functioning lungs, and the ability of
exogenous quinone compounds such as DQ to fully reverse this depolarization, consistent
with hyperoxia-induced decreases in lung complexes I and II activity being the
predominant causes for Δym depolarization. This study is the first to measure hyperoxia-
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induced Δym depolarization in intact lungs, and to demonstrate the utility of this
experimental-computational approach to assess the impact of potential therapies that
target mitochondria in intact functioning lungs.
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APPENDIX I
Protocol for R6G Experiment
Materials required
•
Prepare perfusate (450 ml per lung)
•
Eppendorf 1.7ml
Phase1 – 11*2
Phase 2 – 6*2
Phase 3 – 12*2
Verapamil - 3
FCCP- 1
Rotenone -3
Duroquinone – 1
GSH - 1
•
Sharpie to label
•
Two small bottles to prepare R6G stock 1 and 2
•
Aluminum foil
•
Weighing paper
•
Pipettes
P1000 – Standard curve,
R6G Stock,
Adding R6G to perfusate in phase I
Adding DMSO to Duroquinone
Transferring samples from eppendorfs to cuvette
P200 – Adding DMSO to Rotenone
Adding Verapamil to perfusate
Adding FCCP to perfusate
P100 – Adding stock 1 R6G to stock 2,
Adding rotenone to perfusate in phase I, II, III
Adding Duroquinone to perfusate in phase II and phase III
P10 - Adding R6G to perfusate for standard curve
•
•
•
•
•
•
•
•
•
•
•
•

Pipette tips (P1000, P200, P100, P10)
5ml tubes - 6
DH2O
R6G dye – 1mg/ml of DH2O
Verapamil – prepare three Eppendorf’s for three phases and calculate how much is
required per volume of perfusate
Rotenone
Duroquinone
FCCP for phase III
Timer
Spatula - 2
Mixer
Three beakers for perfusate for the three phases

75
•
•
•
•
•
•

Pressure calibrator
Big syringe with tube to remove liquid from reservoir
Graduated cylinders
Cuvettes
Centrifuge
PTI System

Before experiment
•
Prepare 450ml of perfusate
•
Take eppendorf holders and label them as:
1. Standard curve + verapamil (2*6 1.7ml for each concentration)
2. Phase 1
3. Phase 2
4. Phase 3
•
Label the standard curve eppendorfs with the following concentrations
1. 0
2. 0.03
3. 0.06
4. 0.125
5. 0.25
6. 0.5
•
Prepare eppendorfs for verapamil, rotenone and Duroquinone
•
Label the phase 1 according to the time at which the samples have to be taken:
(Bg, 0s, 40s, 80s, 120s, 3min, 4min, 5min, 7min, 9 min,10min)
•
Label the phase 2 according to the time at which the samples have to be taken:
( 0s, 1min, 2min, 3min, 4min, 5min)
•
Label the phase 3 according to the time at which the samples have to be taken:
(0s ,20s, 40s,60s, 80s,100s, 120s, 3min, 4min,5min, 6min,7min)
•
Set the centrifuge to 4°C for 1min at 10.5x1000 rpm
•
Turn on the incubator and set to 37°C
•
Turn on the PTI system at least 30 min before the start of the experiment
R6G stock
For stock 1, take 1 small bottle and cover it in aluminum foil since R6G is sensitive to
light
•
Label it as 1
•
Weigh 1mg = 0.001g of R6G dye using the weighing paper and add it to stock 1
bottle
•
Add 1ml of DH2O to stock 1 and mix completely to get a concentration of 2.09mM
•
For stock 2, take another bottle and cover with aluminum foil and label as 2
•
Using P1000 pipette add 1.96ml of DH2O and P100 to add 40 µL of stock 1 to stock 2
and mix completely to get a concentration of 41.8µM
•
Keep the stocks in a dark place
•

For verapamil
•
Take 3 eppendorfs and cover with aluminum foil and label as phase I, II, III
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•
•
•

Weigh 10mg of verapamil for 200ml of perfusate and store it in the eppendorf labeled
phase I
Weigh 5mg of verapamil for 100ml of perfusate and store it in the eppendorf labeled
phase II
Weigh 5mg of verapamil for 100ml of perfusate and store it in the eppendorf labeled
phase III

Rotenone stock
Concentration = 100µM
5mg rotenone + 0.125ml DMSO = 100µM of rotenone stock per tube
•
Take 3 eppendorfs and cover with an aluminum foil and label with a sharpie as R1,
R2 and R3.
•
Weigh 5mg of rotenone for each phase and add it to the eppendorf and place in the
dark till experiment.
•
Just before the start of a phase, add 0.125ml of DMSO to the eppendorf containing
Rotenone for that respective phase and place on the mixer to mix well till it is
completely in solution.
•
For 200ml, add 80µL of rotenone stock to 200ml perfusate = 40µM
•
For 100ml, add 40µL of rotenone stock to 100ml perfusate= 40µM
Duroquinone stock
Concentration = 187.5µM
15mg DQ + 0.5mL DMSO = 187.5µM
•
Take 1 eppendorf and cover with an aluminum foil and label with a sharpie as DQ
•
Weigh 15mg of DQ and add it to the eppendorf and place in the dark till experiment.
•
Just before the start of a phase, add 0.5ml of DMSO to the eppendorf containing DQ
and place on the mixer to mix well till it is completely in solution.
•
For 200ml, add 107µL of stock to 200ml perfusate for 100µM final conc
•
For 100ml, add 53.3µL of stock to 100ml perfusate for 100µM final conc
GSH stock
Concentration = 100µM
15.4mg GSH + 0.5mL DH2O= 100µM
•
Take 1 eppendorf and cover with an aluminum foil and label with a sharpie as GSH
•
Weigh 15.4mg of GSH and add it to the eppendorf and place in the dark till
experiment.
•
Just before the start of a phase, add 0.5ml of DH2O to the eppendorf containing GSH
and place on the mixer to mix well till it is completely in solution.
•
For 200ml, add 32µL of stock to 200ml perfusate for 16µM final conc
•
For 100ml, add 16µL of stock to 100ml perfusate for 16µM final conc
R6G PROTOCOL
Phase I
•
Take a beaker with 200ml of perfusate and add the verapamil for phase 1 and mix
well
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•
•
•
•
•
•
•
•
•
•
•

Take 120ml from this 200ml of perfusate and add 0.7177ml of R6G dye from stock 2
to get a concentration of 0.25µM
Pipette 2ml from the perfusate containing the dye and take a measurement using the
PTI system to ensure the concentration of the dye is within range
The remaining 80ml of perfusate with verapamil is used to wash the lung for 3 min.
Take a background sample (bg) in the two 1.7ml eppendorfs from the perfusate
without the dye
Drain the perfusate without R6G from the reservoir
Add 50mL of the perfusate with R6G and add more eventually when collecting
samples to avoid the reservoir from emptying and air entering
Take 0s sample and then turn on the pump
Take samples at 40s, 80s, 120s, 3min, 5min, 7min, 9 min,10min (using 2 1.7ml
eppendorfs per sample)
The flow rate is at 10ml/min, so the samples are taken for 12 seconds each
The samples are collected 6 seconds before and 6 seconds after the mentioned sample
time
The flow is stopped, and the reservoir is washed with perfusate for 3min before the
next phase

Phase II
Before the completion of phase I, take a beaker and fill 100mL of perfusate
•
Add the verapamil from the eppendorf labeled as phase II
•
Mix well and keep ready
•
Before turning the pump back on, take 0s samples
•
Turn the pump on and take samples at 1min, 2min, 3min, 4min, 5min (using 2 1.7ml
eppendorfs per sample time)
•
Stop the flow and wash the reservoir
•

Phase III
Before the completion of phase II, take a beaker and fill 100mL of perfusate and add
the verapamil
•
Using graduated cylinder, measure 75 ml of perfusate with verapamil and transfer to
another beaker
•
Add the FCCP from the eppendorf to the perfusate
•
Mix well and keep ready
•
Before turning the pump back on, take 0s samples
•
Turn the pump on and take samples at 20s, 40s,60s, 80s,100s, 120s, 3min, 4min,5min,
6min,7min (using 2 1.7ml eppendorfs per sample time)
•

Centrifugation
Turn the lights off before centrifugation
•
Centrifuge the samples from each phase at 10.5x1000 rpm @ 4°C for 1min
•
Add each sample time from each phase into a cuvette and measure for fluorescence
•
Make sure to use one cuvette per sample time per phase
•
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Fluorescence reading
•
Switch on the optical imaging system and computer as per protocol
•
Open the Felix software
•
Click on ‘Setup’ -> Time based acquisition
•
Click on acquisition settings tab
•
Set emission: 565nm and excitation: 525nm
•
Change the acquisition time to 300s
•
Set the excitation window to 1.875nm by adjusting the two knobs (1 complete
rotation is 2.5nm)
•
Click ‘Start’ to start acquisition of data

•
•
•
•
•

•

•

•

•
•
•
•

Standard Curve
Take 6 5ml tubes for dilution of R6G
Label them according to their concentrations
(0,0.03,0.06,0.125,0.25,0.5)
Using the P1000 pipette, add 4.5ml of perfusate+verapamil to the tube labeled 0.05
Fill the remaining tubes with 2.25ml of perfusate+verapamil
Tube 0.05µM:
Add 53.8 µL to tube 0.05 and mix
Pipette 2x1ml from the tube to the eppendorfs
Pipette 2.25ml to tube 0.25
Tube 0.25µM:
Mix well
Pipette 2x1ml from the tube to the eppendorfs
Pipette 2.25ml to tube 0.125
Tube 0.125µM: Mix well
Pipette 2x1ml from the tube to the eppendorfs
Pipette 2.25ml to tube 0.06
Tube 0.06µM:
Mix well
Pipette 2x1ml from the tube to the eppendorfs
Pipette 2.25ml to tube 0.03
Tube 0.03µM:
Mix well
Pipette 2x1ml from the tube to the eppendorfs
Tube 0µM:
Pipette 2x1ml from the tube to the eppendorfs containing
only perfusate+verapamil without r6g
Add each sample from each concentration into a cuvette and measure for fluorescence
Make sure to use one cuvette per sample concentration
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APPENDIX II
MATLAB CODE
Simulation Code
1. r6g_single_pass_parameters.m
% Function: simulate concentration of R6G with given parameters
% Input: none
% Output: a datafile containing simulated data
close all
clc
global deltap F deltam_un
% Values for model parameters
vmaxkm = 0.0; % Kpgp Rate (ml/min)
k2_bar = 6.90;% rate constant for binding within the cytoplasm region
kminus2 = 0.178;%Dissociation rate constant within the cytoplasm region
kd3 = 0.018;%Dissociation constant in the mitochondria region
ps2 = 1.07; %Permeability-Surface area product across mitochondrial membrane
deltam = -131.2; % Mitochondrial membrane potential (mV)
deltam_un = -0.1; % Mitochondrial membrane potential after adding FCCP (mV)
ps1 = 46.54; %Permeability-Surface area product across plasma membrane
deltap = -43; %Plasma membrane potential(mV)
F = 10; %Pump flow(ml/min)
% Initial concentrations
Ce_bar = 0; %initial vascular R6G concentration (uM)
Cc = 0; %initial tissue R6G concentration (uM)
Cm = 0; %initial mitochondrial R6G concentration (uM)
CcBc = 0; %intial bound r6g cytoplasm concentration (uM)
Ctub1 = 0; %intial tubing r6g concentration (uM)
%Parameters that are being optimized to their initial points;
y(1) = k2_bar;
y(2) = kminus2;
y(3) = kd3;
y(4) = deltam;
y(5) = ps1;
y_value= [k2_bar, kminus2 , kd3, deltam, ps1 ];
%solving ODE
tspan = [0:0.1:22]';
y0 = [Ctub1 Ce_bar Cc Cm CcBc]; % concentrations (uM)
[tfinal,xfinal] = ode45(@r6g_odes1, tspan, y0, [], y_value); %calling to ode
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%plotting the model
plot(tspan, xfinal(:,2),'linewidth',1);
xlabel('Time (minutes)');
ylabel('Concentration (uM)');
% to write data to a file
file = 'simulation.txt';
write = fopen(file, 'w');
for i=1:length(tspan)
fprintf(write,'%f %f\n', tspan(i), xfinal(i,2));
end
fclose(write);
2. r6g_single_pass_odes.m
% Function: calculate concentration of R6G at a specific time with given parameters
% Input: time: sampling time
% y: concentrations of R6G in tubing region, extravascular region, vascular region, and
mitochondrial region
% Output: Concentration of R6G
function [ dC_dt ] = r6g_odes1(tspan,c, y ,a)
dC_dt = zeros(5,1);
global deltap F deltam_un
% Value of parameters
Ve = 0.85; %Extravascular volume (ml)
Vc = 1.0; %Cytoplasm volume (ml)
Vm = 0.02*Vc; % mitochondrial volume (ml)
Vtub = 4; % tube volume (ml)
alpha = 0.0374158; %ZF/RT, where Z is the valency of the ions, F is Faraday’s constant
(9.684 x 104 C/ mol), R is the gas constant (8.135 J/K*mol), and T is the absolute
temperature in K (273 + temp in Celcius). (mV-1)
Be = 0.5; %BSA concentration (uM)
kd1 = 0.32; %Dissociation constant in the vascular region
vmaxkm=0;
ps2 = 1.07;% Permeability-Surface area product across mitochondrial membrane
%parameters
k2_bar = y(1);
kminus2 = y(2);
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kd3 = y(3);
deltam = y(4);
ps1 = y(5);
% calculate the apparent volume
Vm_app = Vm*(1+(1/kd3)); % apparent volume of the mitochondria extravascular
region
% Concentration of initial R6G based on phase
if tspan >= 0 && tspan <= (t-11.6) %loading phase
Cin = 0.25;
elseif tspan > (t-11.6) && tspan <(t-6.6) % wash phase
Cin = 0;
elseif tspan >= (t-6.6) %uncoupler phase
Cin = 0;
deltam = deltam_un; %Mitochondrial membrane potential with uncoupler (mV)
end
% Free concentration of r6g within the vascular region
Ce = (c(2)/(1+(Be)/(kd1))); %nmol/mL
% flux values
J1 = -((alpha*ps1*deltap)/(exp(-alpha*deltap)-1))*(exp(-alpha*deltap)*Ce-c(3));
%(nmol/min)
J2 = -((alpha*ps2*deltam)/(exp(-alpha*deltam)-1))*(exp(-alpha*deltam)*c(3)-c(4));
%(nmol/min)
% ODEs
dC_dt(1,1) = (1.0/(Vtub))*F*(Cin-c(1)); % tubing region
dC_dt(2,1) = (1/Ve)*(-J1+vmaxkm*c(3)+F*(c(1)-c(2))); % vascular region
dC_dt(3,1) = kminus2*c(5)-k2_bar*c(3)+(1/Vc)*(J1-J2-vmaxkm*c(3)); % cytoplasm
region free
dC_dt(4,1) = (1/Vm_app)*(J2); % mitochondrial region
dC_dt(5,1) = k2_bar*c(3)-kminus2*c(5); % cytoplasm region bound
end
Optimization code
3. data_fit.m
% Function: Find the optimized value for the parameters
% Input: experimental data
% Output: optimized value of parameters
% Format of input data:
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% 1st column: sampling time
% 2nd column: R6G concentration at corresponding sampling time
clear all;
close all;
clc;
global deltap F deltam_un
% load the data file to be fit
y = load (normoxia mean.txt');
time = y(:,1);
data = y(:,2);
timedata = [time];
data = [data];
% Initial value for unknown parameters
k2_bar = 7;% rate constant for binding within the cytoplasm region
deltam = -140.6; % Mitochondrial membrane potential (mV)
deltam_un = 0.1; % Mitochondrial membrane potential after adding FCCP (mV)
ps1 = 46.69; %dye permeability-surface area product across plasma membrane (ml/min)
kminus2 = 0.172;%Dissociation rate constant within the cytoplasm region
kd3 = 0.016;%Dissociation constant in the mitochondria region
%Fixed parameter values
deltap = -43; %Plasma membrane potential (mV)
F = 10; %Flow (ml/min)
vmaxkm = 0.0; % Kpgp Rate (ml/min)
ps2 = 1.12 ;% Permeability-Surface area product across mitochondrial membrane
% Defining the parameters which will be estimated
param = [k2_bar, kminus2, kd3, deltam, ps1 ];
% defining the lower and upper boundary values of the estimated parameter values
lb = [-200 -200 -200 -200 -200];% lower bound
ub = [200 200 200 200 200]; % upper bound
% fitting model to input data and find out the optimized values for parameters using
lsqcurvefit
[x, ssd, residual, ef, outt,lambda, jacobian] = lsqcurvefit(@r6g_par, param, timedata,
data, lb,ub, []);
%parameters
parameter(1,1) = x(1);
parameter(1,2) = x(2);
parameter(1,3) = x(3);

83
parameter(1,4) = x(4);
parameter(1,5) = x(5);
% Display the value of model parameters
fprintf(' k2_bar = %f \n', x(1)); % Display value of k2_bar
fprintf(' kminus2 = %f\n', x(2)); % Display value of kminus2
fprintf(' kd3 = %f\n', x(3)); % Display value of kd3
fprintf(' deltam = %f\n', x(4)); % Display value of deltam
fprintf(' ps1 = %f\n', x(5)); % Display value of ps1
% model_fit = odes(timedata,y,parameter);
model_fit = data+residual;
%Plot the data and the model fit
plot(timedata,data,'ro');
hold on
plot(timedata, model_fit,'b','LineWidth',0.85);
xticks(0:22);
hold off;
legend('Normoxia data','Model fit ');
xlim([0 22]);
ylim([0 0.18]);
xlabel('Time(min)');
ylabel('R6G Venous effluent Concentration (uM)')
%correlation matrix
NP = length(param);
h = inv(jacobian'*jacobian);
for i = 1:NP;
for j = 1:NP;
cc(i,j) = h(i,j)/((h(i,i)*h(j,j))^0.5);
end
end
full(cc)
%confidence intervals (95% confidence, alpha = 0.05)
s_2 = ssd/(length(data) - NP);
for i = 1:NP;
seb(i) = ((s_2)^0.5)*(h(i,i)^0.5);
end
alpha = 0.05;
tt_dis = - tinv(alpha/2, length(data) - length(param)); % tinv is the Student's t inverse
cumulative
%distribution function
seb = seb.*tt_dis;
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seb;
%%%%%%%
4.
r6g_odes.m
% Function: calculate concentration of R6G at a specific time with given parameters
based on rhodamine distribution model
% Input: time: sampling time
% y: concentrations of R6G in tubing region, extravascular region, vascular region and
mitochondrial region
% Output: Concentration of R6G
function [ dy ] = r6g_odes(timedata,y,x)
%create vector of zeros
dy = zeros(5,1);
global deltap F deltam_un
% Value of parameters
Ve = 0.85; %vascular volume (ml)
Vc = 1; %lung tissue volume (ml)
Vm = 0.02*Vc; % mitochondrial volume (ml)
Vtub = 4; % tube volume (ml)
alpha = 0.0374158; %ZF/RT, constant dependent on the universal gas constant (R),
Faraday constant (F), R6G valence (Z) , and absolute temperature (T)
Be = 0.5; %BSA concentration (uM)
kd1 = 0.32; % k-1/k1, Dissociation constant in the vascular region (umol-1*min-1)
vmaxkm = 0; % Kpgp rate (ml/min)
ps2 = 1.12;% Permeability-Surface area product across mitochondrial membrane
% Estimate Parameter values
k2_bar = x(1);
kminus2 = x(2);
kd3 = x(3);
deltam = x(4);
ps1 = x(5);
% calculate apparent volume
V3 = Vm*(1+(1/kd3)); %Apparent mitochondrial volume (ml)
% final time point
t = 22;
% Concentration of R6G based on phase
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if timedata >= 0 && timedata <= (t-11.6) %loading phase
Cin = 0.25; % R6g Concentration
elseif timedata > (t-11.6) && timedata <(t-6.6) % wash phase
Cin = 0;% R6g Concentration
elseif timedata >= (t-6.6) %uncoupler phase
Cin = 0;% R6g Concentration
deltam = deltam_un; %Mitochondrial membrane potential with uncoupler (mV)
end
%Concentration of r6g in the vascular region
Ce = (y(2)/(1+(Be)/(kd1)));
% Flux values
J1 = -((alpha*ps1*deltap)/(exp(-alpha*deltap)-1))*(exp(-alpha*deltap)*Ce-y(3)); %Dye
flux across plasma membrane (nmol/min)
J2 = -((alpha*ps2*deltam)/(exp(-alpha*deltam)-1))*(exp(-alpha*deltam)*y(3)-y(4));
%Dye flux across mitochondrial membrane (nmol/min)
dy(1,1) = (1.0/(Vtub))*F*(Cin-y(1)); % tubing region
dy(2,1) = (1/Ve)*(-J1+vmaxkm*y(3)+F*(y(1)-y(2))); % extracellular/vascular region
units = nmol/mL*min
dy(3,1) = kminus2*y(5)-k2_bar*y(3)+(1/Vc)*(J1-J2-vmaxkm*y(3)); % cytoplasm region
free
dy(4,1) = (1/V3)*(J2); % mitochondrial region units = nmol/mL*min
dy(5,1) = k2_bar*y(3)-kminus2*y(5); % cytoplasm region bound
end
5. r6g_par.m
% Function: calculate concentration of R6G with given parameters
% Input: y: given parameters
% Output: An array of concentration of R6G
function output = r6g_par(x, timedata)
global deltap F deltam_un
% Set parameters that are being optimized to their initial points;
k2_bar = x(1);
kminus2 = x(2);
kd3 = x(3);
deltam = x(4);
ps1 = x(5);
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parameter_values = [k2_bar,kminus2, kd3, deltam, ps1];
%Initial conditions for ODE
Ce_bar = 0; %initial vascular R6G concentration (uM)
Cc = 0; %initial tissue R6G concentration (uM)
Cm = 0; %initial mitochondrial R6G concentration (uM)
CcBc = 0; %intial bound r6g cytoplasm concentration (uM)
Ctub1 = 0; %intial tubing r6g concentration (uM)
x0 = [Ctub1 Ce_bar Cc Cm CcBc];
% Calling ODE function
[T,Y] = ode45(@odes, timedata, x0, [], parameter_values);
output = Y(:,2);

